Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent or treat AIDS. Some vaccines containing antigens are recombinantly produced.
Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.
Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease.
Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.
Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins.
Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers.
Two or more vaccines in a single dosage form.
Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease.
Vaccines or candidate vaccines designed to prevent SAIDS; (SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME); and containing inactivated SIMIAN IMMUNODEFICIENCY VIRUS or type D retroviruses or some of their component antigens.
Species of the genus LENTIVIRUS, subgenus primate immunodeficiency viruses (IMMUNODEFICIENCY VIRUSES, PRIMATE), that induces acquired immunodeficiency syndrome in monkeys and apes (SAIDS). The genetic organization of SIV is virtually identical to HIV.
Antibodies reactive with HIV ANTIGENS.
A species of the genus MACACA inhabiting India, China, and other parts of Asia. The species is used extensively in biomedical research and adapts very well to living with humans.
Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.
Vaccines consisting of one or more antigens that stimulate a strong immune response. They are purified from microorganisms or produced by recombinant DNA techniques, or they can be chemically synthesized peptides.
Semisynthetic vaccines consisting of polysaccharide antigens from microorganisms attached to protein carrier molecules. The carrier protein is recognized by macrophages and T-cells thus enhancing immunity. Conjugate vaccines induce antibody formation in people not responsive to polysaccharide alone, induce higher levels of antibody, and show a booster response on repeated injection.
Acquired defect of cellular immunity that occurs naturally in macaques infected with SRV serotypes, experimentally in monkeys inoculated with SRV or MASON-PFIZER MONKEY VIRUS; (MPMV), or in monkeys infected with SIMIAN IMMUNODEFICIENCY VIRUS.
The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.
Any immunization following a primary immunization and involving exposure to the same or a closely related antigen.
An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.
Vaccines made from antigens arising from any of the four strains of Plasmodium which cause malaria in humans, or from P. berghei which causes malaria in rodents.
The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50).
Antigens associated with specific proteins of the human adult T-cell immunodeficiency virus (HIV); also called HTLV-III-associated and lymphadenopathy-associated virus (LAV) antigens.
Retroviral proteins, often glycosylated, coded by the envelope (env) gene. They are usually synthesized as protein precursors (POLYPROTEINS) and later cleaved into the final viral envelope glycoproteins by a viral protease.
Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.
Vaccines or candidate vaccines used to prevent PAPILLOMAVIRUS INFECTIONS. Human vaccines are intended to reduce the incidence of UTERINE CERVICAL NEOPLASMS, so they are sometimes considered a type of CANCER VACCINES. They are often composed of CAPSID PROTEINS, especially L1 protein, from various types of ALPHAPAPILLOMAVIRUS.
Immunoglobulins produced in response to VIRAL ANTIGENS.
Vaccines or candidate vaccines used to prevent infection with NEISSERIA MENINGITIDIS.
External envelope protein of the human immunodeficiency virus which is encoded by the HIV env gene. It has a molecular weight of 120 kDa and contains numerous glycosylation sites. Gp120 binds to cells expressing CD4 cell-surface antigens, most notably T4-lymphocytes and monocytes/macrophages. Gp120 has been shown to interfere with the normal function of CD4 and is at least partly responsible for the cytopathic effect of HIV.
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).
Vaccines or candidate vaccines containing inactivated hepatitis B or some of its component antigens and designed to prevent hepatitis B. Some vaccines may be recombinantly produced.
A live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had measles or been immunized with live measles vaccine and have no serum antibodies against measles. Children are usually immunized with measles-mumps-rubella combination vaccine. (From Dorland, 28th ed)
A suspension of killed Bordetella pertussis organisms, used for immunization against pertussis (WHOOPING COUGH). It is generally used in a mixture with diphtheria and tetanus toxoids (DTP). There is an acellular pertussis vaccine prepared from the purified antigenic components of Bordetella pertussis, which causes fewer adverse reactions than whole-cell vaccine and, like the whole-cell vaccine, is generally used in a mixture with diphtheria and tetanus toxoids. (From Dorland, 28th ed)
Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).
Vaccines or candidate vaccines containing antigenic polysaccharides from Haemophilus influenzae and designed to prevent infection. The vaccine can contain the polysaccharides alone or more frequently polysaccharides conjugated to carrier molecules. It is also seen as a combined vaccine with diphtheria-tetanus-pertussis vaccine.
An active immunizing agent and a viable avirulent attenuated strain of Mycobacterium tuberculosis, var. bovis, which confers immunity to mycobacterial infections. It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity.
A suspension of formalin-inactivated poliovirus grown in monkey kidney cell tissue culture and used to prevent POLIOMYELITIS.
Vaccines or candidate vaccines used to prevent and treat RABIES. The inactivated virus vaccine is used for preexposure immunization to persons at high risk of exposure, and in conjunction with rabies immunoglobulin, for postexposure prophylaxis.
Vaccines or candidate vaccines used to prevent infection with ROTAVIRUS.
Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it.
Vaccines or candidate vaccines used to prevent infection with VIBRIO CHOLERAE. The original cholera vaccine consisted of killed bacteria, but other kinds of vaccines now exist.
Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.
Proteins encoded by the ENV GENE of the HUMAN IMMUNODEFICIENCY VIRUS.
Vaccines used to prevent TYPHOID FEVER and/or PARATYPHOID FEVER which are caused by various species of SALMONELLA. Attenuated, subunit, and inactivated forms of the vaccines exist.
A live VACCINIA VIRUS vaccine of calf lymph or chick embryo origin, used for immunization against smallpox. It is now recommended only for laboratory workers exposed to smallpox virus. Certain countries continue to vaccinate those in the military service. Complications that result from smallpox vaccination include vaccinia, secondary bacterial infections, and encephalomyelitis. (Dorland, 28th ed)
Vaccines or candidate vaccines used to prevent or treat TUBERCULOSIS.
A live, attenuated varicella virus vaccine used for immunization against chickenpox. It is recommended for children between the ages of 12 months and 13 years.
A vaccine consisting of DIPHTHERIA TOXOID; TETANUS TOXOID; and whole-cell PERTUSSIS VACCINE. The vaccine protects against diphtheria, tetanus, and whooping cough.
An envelope protein of the human immunodeficiency virus that is encoded by the HIV env gene. It has a molecular weight of 160,000 kDa and contains numerous glycosylation sites. It serves as a precursor for both the HIV ENVELOPE PROTEIN GP120 and the HIV ENVELOPE PROTEIN GP41.
Proteins coded by the retroviral gag gene. The products are usually synthesized as protein precursors or POLYPROTEINS, which are then cleaved by viral proteases to yield the final products. Many of the final products are associated with the nucleoprotein core of the virion. gag is short for group-specific antigen.
A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.
DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition.
Vaccines used to prevent infection by MUMPS VIRUS. Best known is the live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had mumps or been immunized with live mumps vaccine. Children are usually immunized with measles-mumps-rubella combination vaccine.
The quantity of measurable virus in a body fluid. Change in viral load, measured in plasma, is sometimes used as a SURROGATE MARKER in disease progression.
The type species of ORTHOPOXVIRUS, related to COWPOX VIRUS, but whose true origin is unknown. It has been used as a live vaccine against SMALLPOX. It is also used as a vector for inserting foreign DNA into animals. Rabbitpox virus is a subspecies of VACCINIA VIRUS.
Vaccines or candidate vaccines used to prevent infection with hepatitis A virus (HEPATOVIRUS).
Schedule giving optimum times usually for primary and/or secondary immunization.
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
A combined vaccine used to prevent MEASLES; MUMPS; and RUBELLA.
Vaccines or candidate vaccines used to prevent STREPTOCOCCAL INFECTIONS.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Vaccines or candidate vaccines used to prevent ANTHRAX.
Vaccines or candidate vaccines used to prevent infection with DENGUE VIRUS. These include live-attenuated, subunit, DNA, and inactivated vaccines.
A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes.
Vaccines using VIROSOMES as the antigen delivery system that stimulates the desired immune response.
Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.
DNA sequences that form the coding region for the viral envelope (env) proteins in retroviruses. The env genes contain a cis-acting RNA target sequence for the rev protein (= GENE PRODUCTS, REV), termed the rev-responsive element (RRE).
Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role.
Any vaccine raised against any virus or viral derivative that causes hepatitis.
A live vaccine containing attenuated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used for routine immunization of children against polio. This vaccine induces long-lasting intestinal and humoral immunity. Killed vaccine induces only humoral immunity. Oral poliovirus vaccine should not be administered to immunocompromised individuals or their household contacts. (Dorland, 28th ed)
Vaccine used to prevent YELLOW FEVER. It consists of a live attenuated 17D strain of the YELLOW FEVER VIRUS.
Immunoglobulins produced in a response to BACTERIAL ANTIGENS.
A suspension of killed Yersinia pestis used for immunizing people in enzootic plague areas.
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
Suspensions of attenuated or killed fungi administered for the prevention or treatment of infectious fungal disease.
Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen.
A live attenuated virus vaccine of duck embryo or human diploid cell tissue culture origin, used for routine immunization of children and for immunization of nonpregnant adolescent and adult females of childbearing age who are unimmunized and do not have serum antibodies to rubella. Children are usually immunized with measles-mumps-rubella combination vaccine. (Dorland, 28th ed)
Vaccines that are produced by using only the antigenic part of the disease causing organism. They often require a "booster" every few years to maintain their effectiveness.
The presence of viruses in the blood.
Antigenic determinants recognized and bound by the T-cell receptor. Epitopes recognized by the T-cell receptor are often located in the inner, unexposed side of the antigen, and become accessible to the T-cell receptors after proteolytic processing of the antigen.
Vaccines or candidate vaccines used to prevent infection with SALMONELLA. This includes vaccines used to prevent TYPHOID FEVER or PARATYPHOID FEVER; (TYPHOID-PARATYPHOID VACCINES), and vaccines used to prevent nontyphoid salmonellosis.
The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include pharmacokinetics, dosage analysis, or drug administration analysis.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
Vaccines using supra-molecular structures composed of multiple copies of recombinantly expressed viral structural proteins. They are often antigentically indistinguishable from the virus from which they were derived.
Vaccines or candidate vaccines used to prevent EBOLA HEMORRHAGIC FEVER.
An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia.
Products of the retroviral NEF GENE. They play a role as accessory proteins that influence the rate of viral infectivity and the destruction of the host immune system. nef gene products were originally found as factors that trans-suppress viral replication and function as negative regulators of transcription. nef stands for negative factor.
The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle.
Live vaccines prepared from microorganisms which have undergone physical adaptation (e.g., by radiation or temperature conditioning) or serial passage in laboratory animal hosts or infected tissue/cell cultures, in order to produce avirulent mutant strains capable of inducing protective immunity.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Combined vaccines consisting of DIPHTHERIA TOXOID; TETANUS TOXOID; and an acellular form of PERTUSSIS VACCINE. At least five different purified antigens of B. pertussis have been used in various combinations in these vaccines.
The interaction of persons or groups of persons representing various nations in the pursuit of a common goal or interest.
Vaccines or candidate vaccines used to prevent infection with CYTOMEGALOVIRUS.
Organized services to administer immunization procedures in the prevention of various diseases. The programs are made available over a wide range of sites: schools, hospitals, public health agencies, voluntary health agencies, etc. They are administered to an equally wide range of population groups or on various administrative levels: community, municipal, state, national, international.
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
A combined vaccine used to prevent infection with diphtheria and tetanus toxoid. This is used in place of DTP vaccine (DIPHTHERIA-TETANUS-PERTUSSIS VACCINE) when PERTUSSIS VACCINE is contraindicated.
Vaccines used to prevent POLIOMYELITIS. They include inactivated (POLIOVIRUS VACCINE, INACTIVATED) and oral vaccines (POLIOVIRUS VACCINE, ORAL).
Delivery of medications through the nasal mucosa.
Vaccines or candidate vaccines used to prevent or treat both enterotoxigenic and enteropathogenic Escherichia coli infections.
Vaccines or candidate vaccines used to prevent infection with WEST NILE VIRUS.
Serologic tests in which a known quantity of antigen is added to the serum prior to the addition of a red cell suspension. Reaction result is expressed as the smallest amount of antigen which causes complete inhibition of hemagglutination.
Vaccines or candidate vaccines used to prevent bacillary dysentery (DYSENTERY, BACILLARY) caused by species of SHIGELLA.
The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS.
An attenuated vaccine used to prevent and/or treat HERPES ZOSTER, a disease caused by HUMAN HERPESVIRUS 3.
Antibody-mediated immune response. Humoral immunity is brought about by ANTIBODY FORMATION, resulting from TH2 CELLS activating B-LYMPHOCYTES, followed by COMPLEMENT ACTIVATION.
Sorbitan mono-9-octadecanoate poly(oxy-1,2-ethanediyl) derivatives; complex mixtures of polyoxyethylene ethers used as emulsifiers or dispersing agents in pharmaceuticals.
A bacterial vaccine for the prevention of brucellosis in man and animal. Brucella abortus vaccine is used for the immunization of cattle, sheep, and goats.
Sites on an antigen that interact with specific antibodies.
Vaccines or candidate vaccines used to prevent infection by any virus from the family HERPESVIRIDAE.
The forcing into the skin of liquid medication, nutrient, or other fluid through a hollow needle, piercing the top skin layer.
Vaccines or candidate vaccines used to prevent infection with LEISHMANIA.
A subtype of INFLUENZA A VIRUS with the surface proteins hemagglutinin 1 and neuraminidase 1. The H1N1 subtype was responsible for the Spanish flu pandemic of 1918.
A compound with many biomedical applications: as a gastric antacid, an antiperspirant, in dentifrices, as an emulsifier, as an adjuvant in bacterins and vaccines, in water purification, etc.
Genotypic differences observed among individuals in a population.
Substances elaborated by bacteria that have antigenic activity.
Aluminum metal sulfate compounds used medically as astringents and for many industrial purposes. They are used in veterinary medicine for the treatment of ulcerative stomatitis, leukorrhea, conjunctivitis, pharyngitis, metritis, and minor wounds.
Vaccines or candidate vaccines used to prevent infection with viruses from the genus SIMPLEXVIRUS. This includes vaccines for HSV-1 and HSV-2.
The formaldehyde-inactivated toxin of Corynebacterium diphtheriae. It is generally used in mixtures with TETANUS TOXOID and PERTUSSIS VACCINE; (DTP); or with tetanus toxoid alone (DT for pediatric use and Td, which contains 5- to 10-fold less diphtheria toxoid, for other use). Diphtheria toxoid is used for the prevention of diphtheria; DIPHTHERIA ANTITOXIN is for treatment.
The relationships of groups of organisms as reflected by their genetic makeup.
Vaccines or candidate vaccines used to prevent infection with RESPIRATORY SYNCYTIAL VIRUSES.
Established cell cultures that have the potential to propagate indefinitely.
Deoxyribonucleic acid that makes up the genetic material of viruses.
Protection conferred on a host by inoculation with one strain or component of a microorganism that prevents infection when later challenged with a similar strain. Most commonly the microorganism is a virus.
Vaccines or candidate vaccines used to prevent infection with Japanese B encephalitis virus (ENCEPHALITIS VIRUS, JAPANESE).
Administration of a vaccine to large populations in order to elicit IMMUNITY.
An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.
Vaccines or candidate vaccines used to prevent conception.
Vaccines or candidate vaccines derived from edible plants. Transgenic plants (PLANTS, TRANSGENIC) are used as recombinant protein production systems and the edible plant tissue functions as an oral vaccine.
A respiratory infection caused by BORDETELLA PERTUSSIS and characterized by paroxysmal coughing ending in a prolonged crowing intake of breath.
Active immunization where vaccine is administered for therapeutic or preventive purposes. This can include administration of immunopotentiating agents such as BCG vaccine and Corynebacterium parvum as well as biological response modifiers such as interferons, interleukins, and colony-stimulating factors in order to directly stimulate the immune system.
Any part or derivative of any protozoan that elicits immunity; malaria (Plasmodium) and trypanosome antigens are presently the most frequently encountered.
The relationship between an elicited ADAPTIVE IMMUNE RESPONSE and the dose of the vaccine administered.
A highly contagious infectious disease caused by MORBILLIVIRUS, common among children but also seen in the nonimmune of any age, in which the virus enters the respiratory tract via droplet nuclei and multiplies in the epithelial cells, spreading throughout the MONONUCLEAR PHAGOCYTE SYSTEM.
The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES.
Vaccines for the prevention of diseases caused by various species of Rickettsia.
An acute, highly contagious, often fatal infectious disease caused by an orthopoxvirus characterized by a biphasic febrile course and distinctive progressive skin eruptions. Vaccination has succeeded in eradicating smallpox worldwide. (Dorland, 28th ed)
Emergency care or treatment given to a person who suddenly becomes ill or injured before full medical services become available.
Nonsusceptibility to the pathogenic effects of foreign microorganisms or antigenic substances as a result of antibody secretions of the mucous membranes. Mucosal epithelia in the gastrointestinal, respiratory, and reproductive tracts produce a form of IgA (IMMUNOGLOBULIN A, SECRETORY) that serves to protect these ports of entry into the body.
Vaccines or candidate vaccines used to prevent infection with parainfluenza viruses in humans and animals.
Infection with any of the rotaviruses. Specific infections include human infantile diarrhea, neonatal calf diarrhea, and epidemic diarrhea of infant mice.
A subtype of INFLUENZA A VIRUS comprised of the surface proteins hemagglutinin 5 and neuraminidase 1. The H5N1 subtype, frequently referred to as the bird flu virus, is endemic in wild birds and very contagious among both domestic (POULTRY) and wild birds. It does not usually infect humans, but some cases have been reported.
A subtype of INFLUENZA A VIRUS comprised of the surface proteins hemagglutinin 3 and neuraminidase 2. The H3N2 subtype was responsible for the Hong Kong flu pandemic of 1968.
Species of the genus INFLUENZAVIRUS B that cause HUMAN INFLUENZA and other diseases primarily in humans. Antigenic variation is less extensive than in type A viruses (INFLUENZA A VIRUS) and consequently there is no basis for distinct subtypes or variants. Epidemics are less likely than with INFLUENZA A VIRUS and there have been no pandemics. Previously only found in humans, Influenza B virus has been isolated from seals which may constitute the animal reservoir from which humans are exposed.
Vaccines or candidate vaccines used to prevent PSEUDORABIES (Aujeszky's disease), a herpesvirus of swine and other animals.
Substances elaborated by viruses that have antigenic activity.
Membrane glycoproteins from influenza viruses which are involved in hemagglutination, virus attachment, and envelope fusion. Fourteen distinct subtypes of HA glycoproteins and nine of NA glycoproteins have been identified from INFLUENZA A VIRUS; no subtypes have been identified for Influenza B or Influenza C viruses.
Neoplasms of the skin and mucous membranes caused by papillomaviruses. They are usually benign but some have a high risk for malignant progression.
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)
The process of keeping pharmaceutical products in an appropriate location.
Acute VIRAL CNS INFECTION affecting mammals, including humans. It is caused by RABIES VIRUS and usually spread by contamination with virus-laden saliva of bites inflicted by rabid animals. Important animal vectors include the dog, cat, bat, fox, raccoon, skunk, and wolf.
A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell.
Virus diseases caused by the ORTHOMYXOVIRIDAE.
Proteins found in any species of protozoan.
The type species of the genus INFLUENZAVIRUS A that causes influenza and other diseases in humans and animals. Antigenic variation occurs frequently between strains, allowing classification into subtypes and variants. Transmission is usually by aerosol (human and most non-aquatic hosts) or waterborne (ducks). Infected birds shed the virus in their saliva, nasal secretions, and feces.
Sudden increase in the incidence of a disease. The concept includes EPIDEMICS and PANDEMICS.
Infections with bacteria of the species NEISSERIA MENINGITIDIS.
Vaccines used in conjunction with diagnostic tests to differentiate vaccinated animals from carrier animals. Marker vaccines can be either a subunit or a gene-deleted vaccine.
A type of H. influenzae isolated most frequently from biotype I. Prior to vaccine availability, it was a leading cause of childhood meningitis.
Process of determining and distinguishing species of bacteria or viruses based on antigens they share.
Specialized cells of the hematopoietic system that have branch-like extensions. They are found throughout the lymphatic system, and in non-lymphoid tissues such as SKIN and the epithelia of the intestinal, respiratory, and reproductive tracts. They trap and process ANTIGENS, and present them to T-CELLS, thereby stimulating CELL-MEDIATED IMMUNITY. They are different from the non-hematopoietic FOLLICULAR DENDRITIC CELLS, which have a similar morphology and immune system function, but with respect to humoral immunity (ANTIBODY PRODUCTION).
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
The type species of the FLAVIVIRUS genus. Principal vector transmission to humans is by AEDES spp. mosquitoes.
An acute infectious disease caused by RUBULAVIRUS, spread by direct contact, airborne droplet nuclei, fomites contaminated by infectious saliva, and perhaps urine, and usually seen in children under the age of 15, although adults may also be affected. (From Dorland, 28th ed)
Elements of limited time intervals, contributing to particular results or situations.
Strains of Neisseria meningitidis which are the most common ones causing infections or disease in infants. Serogroup B strains are isolated most frequently in sporadic cases, and are less common in outbreaks and epidemics.
The non-susceptibility to infection of a large group of individuals in a population. A variety of factors can be responsible for herd immunity and this gives rise to the different definitions used in the literature. Most commonly, herd immunity refers to the case when, if most of the population is immune, infection of a single individual will not cause an epidemic. Also, in such immunized populations, susceptible individuals are not likely to become infected. Herd immunity can also refer to the case when unprotected individuals fail to contract a disease because the infecting organism has been banished from the population.
Vaccines or candidate vaccines used to prevent LYME DISEASE.
Layers of protein which surround the capsid in animal viruses with tubular nucleocapsids. The envelope consists of an inner layer of lipids and virus specified proteins also called membrane or matrix proteins. The outer layer consists of one or more types of morphological subunits called peplomers which project from the viral envelope; this layer always consists of glycoproteins.
Epidemics of infectious disease that have spread to many countries, often more than one continent, and usually affecting a large number of people.
The expelling of virus particles from the body. Important routes include the respiratory tract, genital tract, and intestinal tract. Virus shedding is an important means of vertical transmission (INFECTIOUS DISEASE TRANSMISSION, VERTICAL).
A disease caused by tetanospasmin, a powerful protein toxin produced by CLOSTRIDIUM TETANI. Tetanus usually occurs after an acute injury, such as a puncture wound or laceration. Generalized tetanus, the most common form, is characterized by tetanic muscular contractions and hyperreflexia. Localized tetanus presents itself as a mild condition with manifestations restricted to muscles near the wound. It may progress to the generalized form.
Nonsusceptibility to the invasive or pathogenic effects of foreign microorganisms or to the toxic effect of antigenic substances.
Vaccines or candidate vaccines used to prevent or treat PSEUDOMONAS INFECTIONS.
The giving of drugs, chemicals, or other substances by mouth.
A fulminant infection of the meninges and subarachnoid fluid by the bacterium NEISSERIA MENINGITIDIS, producing diffuse inflammation and peri-meningeal venous thromboses. Clinical manifestations include FEVER, nuchal rigidity, SEIZURES, severe HEADACHE, petechial rash, stupor, focal neurologic deficits, HYDROCEPHALUS, and COMA. The organism is usually transmitted via nasopharyngeal secretions and is a leading cause of meningitis in children and young adults. Organisms from Neisseria meningitidis serogroups A, B, C, Y, and W-135 have been reported to cause meningitis. (From Adams et al., Principles of Neurology, 6th ed, pp689-701; Curr Opin Pediatr 1998 Feb;10(1):13-8)

Proliferative responses to human immunodeficiency virus type 1 (HIV-1) gp120 peptides in HIV-1-infected individuals immunized with HIV-1 rgp120 or rgp160 compared with nonimmunized and uninfected controls. (1/1614)

The proliferative responses to a series of peptides constituting the human immunodeficiency virus type 1 (HIV-1) gp120 sequence were evaluated in 19 HIV-1-infected rgp160 vaccine recipients, 17 HIV-1-infected rgp120 vaccine recipients, 15 HIV-1-infected placebo recipients, and 18 HIV-1-uninfected controls. Many regions of the gp120 molecule were found to contribute proliferative epitopes, although there were clearly regions of relative dominance and silence. Vaccine recipients tended to have broader, more robust, and more frequent peptide recognition than the placebo recipients. Despite the considerable variability in the pattern of peptide recognition among individuals, there was a striking similarity between the rgp160 and rgp120 vaccinee groups as a whole. Low-risk HIV-1-uninfected individuals may react to a few peptides within the gp120 sequence as well, despite a lack of significant response to the whole gp120 protein.  (+info)

Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance. (2/1614)

The kinetics of T-helper immune responses generated in 16 mature outbred rhesus monkeys (Macaca mulatta) within a 10-month period by three different human immunodeficiency virus type 1 (HIV-1) vaccine strategies were compared. Immune responses to monomeric recombinant gp120SF2 (rgp120) when the protein was expressed in vivo by DNA immunization or when it was delivered as a subunit protein vaccine formulated either with the MF59 adjuvant or by incorporation into immune-stimulating complexes (ISCOMs) were compared. Virus-neutralizing antibodies (NA) against HIV-1SF2 reached similar titers in the two rgp120SF2 protein-immunized groups, but the responses showed different kinetics, while NA were delayed and their levels were low in the DNA-immunized animals. Antigen-specific gamma interferon (IFN-gamma) T-helper (type 1-like) responses were detected in the DNA-immunized group, but only after the fourth immunization, and the rgp120/MF59 group generated both IFN-gamma and interleukin-4 (IL-4) (type 2-like) responses that appeared after the third immunization. In contrast, rgp120/ISCOM-immunized animals rapidly developed marked IL-2, IFN-gamma (type 1-like), and IL-4 responses that peaked after the second immunization. To determine which type of immune responses correlated with protection from infection, all animals were challenged intravenously with 50 50% infective doses of a rhesus cell-propagated, in vivo-titrated stock of a chimeric simian immunodeficiency virus-HIVSF13 construct. Protection was observed in the two groups receiving the rgp120 subunit vaccines. Half of the animals in the ISCOM group were completely protected from infection. In other subunit vaccinees there was evidence by multiple assays that virus detected at 2 weeks postchallenge was effectively cleared. Early induction of potent type 1- as well as type 2-like T-helper responses induced the most-effective immunity.  (+info)

Intracellular adhesion molecule-1 modulates beta-chemokines and directly costimulates T cells in vivo. (3/1614)

The potential roles of adhesion molecules in the expansion of T cell-mediated immune responses in the periphery were examined using DNA immunogen constructs as model antigens. We coimmunized cDNA expression cassettes encoding the adhesion molecules intracellular adhesion molecule-1 (ICAM-1), lymphocyte function associated-3 (LFA-3), and vascular cell adhesion molecule-1 (VCAM-1) along with DNA immunogens, and we analyzed the resulting antigen-specific immune responses. We observed that antigen-specific T-cell responses can be enhanced by the coexpression of DNA immunogen and adhesion molecules ICAM-1 and LFA-3. Coexpression of ICAM-1 or LFA-3 molecules along with DNA immunogens resulted in a significant enhancement of T-helper cell proliferative responses. In addition, coimmunization with pCICAM-1 (and more moderately with pCLFA-3) resulted in a dramatic enhancement of CD8-restricted cytotoxic T-lymphocyte responses. Although VCAM-1 and ICAM-1 are similar in size, VCAM-1 coimmunization did not have any measurable effect on cell-mediated responses. These results suggest that ICAM-1 and LFA-3 provide direct T-cell costimulation. These observations are further supported by the finding that coinjection with ICAM-1 dramatically enhanced the level of interferon-gamma (IFN-gamma) and beta-chemokines macrophage inflammatory protein-1alpha (MIP-1alpha), MIP-1beta, and regulated on activation normal T-cell expression and secreted (RANTES) produced by stimulated T cells. Through comparative studies, we observed that ICAM-1/LFA-1 T-cell costimulatory pathways are independent of CD86/CD28 pathways and that they may synergistically expand T-cell responses in vivo.  (+info)

Rectal transmission of human immunodeficiency virus type 1 to chimpanzees. (4/1614)

Inoculation of chimpanzees with human immunodeficiency virus type 1 (HIV-1) has been used as a model system to define mechanisms of pathogenesis and to test protective efficacy of candidate HIV-1 vaccines. In most of these studies, the animals were inoculated intravenously. However, because HIV-1 is transmitted primarily across mucosal surfaces, future evaluations of vaccines should employ mucosal routes for administering infectious virus to immunized animals. To develop a model of rectal transmission of HIV-1, chimpanzees were exposed without trauma to 4 different HIV-1 strains at doses ranging from 200 to 10,000 TCIDs. Infection, characterized by seroconversion and repeated isolation of virus from lymphocytes, was established in 1 of 5 animals. This animal was sequentially inoculated with a subtype B and then an E strain and was infected with both strains. The results show that rectal exposure of adult chimpanzees to cell-free HIV-1 was not an efficient mode of transmission in this cohort.  (+info)

Mucosal vaccination strategies for women. (5/1614)

Women were immunized orally, rectally, or vaginally with a recombinant cholera toxin B-containing vaccine to determine which of these mucosal immunization routes generate the greatest levels of antibody in the female genital tract and rectum. ELISA was used to measure concentrations of cholera toxin B-specific IgA and IgG antibody in serum and secretions before and after three immunizations. Each immunization route similarly increased specific IgG in serum and specific IgA in saliva. Only the vaginal route increased IgA antibodies in genital tract secretions and could be shown to induce a local IgG response. However, vaginal immunization failed to produce antibody in the rectum. In a similar fashion, rectal immunization elicited highest concentrations of locally derived IgA and IgG antibody in the rectum but was ineffective for generating antibody in the genital tract. The data suggest that local immunization may induce the greatest immune responses in the female genital tract and rectum of humans.  (+info)

Detection of intracellular antigen-specific cytokines in human T cell populations. (6/1614)

Determination of antigen-specific cytokine responses of T lymphocytes after vaccination is made difficult by the low frequency of responder cells. In order to detect these responses, the profile of intracellular cytokines was analyzed using flow cytometry after antigenic expansion. Peripheral blood mononuclear cells were stimulated with antigens for 5 days, further expanded with interleukin (IL)-2, and then restimulated on day 10. Cytokine production was detected by intracellular staining with monoclonal antibodies after saponin-based permeabilization. Influenza expansion resulted in specific interferon-gamma (IFN-gamma) production of 6%-20%, with less IL-4 production (0%-2%). Tetanus toxoid resulted in even greater production. IL-4 and IFN-gamma were produced mainly by memory cells of the CD45RO+ phenotype. IFN-gamma production was contributed by both CD4 and CD8 populations. These methods were then applied to a clinical trial of a candidate human immunodeficiency virus type 1 vaccine. Antigen-specific increases in IFN-gamma were measured, which corresponded to antibody production, lymphoproliferation, and skin testing.  (+info)

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. (7/1614)

The role of antibody in protection against human immunodeficiency virus (HIV-1) has been difficult to study in animal models because most primary HIV-1 strains do not infect nonhuman primates. Using a chimeric simian/human immunodeficiency virus (SHIV) based on the envelope of a primary isolate (HIV-89.6), we performed passive-transfer experiments in rhesus macaques to study the role of anti-envelope antibodies in protection. Based on prior in vitro data showing neutralization synergy by antibody combinations, we evaluated HIV immune globulin (HIVIG), and human monoclonal antibodies (MAbs) 2F5 and 2G12 given alone, compared with the double combination 2F5/2G12 and the triple combination HIVIG/2F5/2G12. Antibodies were administered 24 h prior to intravenous challenge with the pathogenic SHIV-89.6PD. Six control monkeys displayed high plasma viremia, rapid CD4(+)-cell decline, and clinical AIDS within 14 weeks. Of six animals given HIVIG/2F5/2G12, three were completely protected; the remaining three animals became SHIV infected but displayed reduced plasma viremia and near normal CD4(+)-cell counts. One of three monkeys given 2F5/2G12 exhibited only transient evidence of infection; the other two had marked reductions in viral load. All monkeys that received HIVIG, 2F5, or 2G12 alone became infected and developed high-level plasma viremia. However, compared to controls, monkeys that received HIVIG or MAb 2G12 displayed a less profound drop in CD4(+) T cells and a more benign clinical course. These data indicate a general correlation between in vitro neutralization and protection and suggest that a vaccine that elicits neutralizing antibody should have a protective effect against HIV-1 infection or disease.  (+info)

Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. (8/1614)

Overcoming preexisting immunity to vaccinia virus in the adult population is a key requirement for development of otherwise potent recombinant vaccinia vaccines. Based on our observation that s.c. immunization with vaccinia induces cellular and antibody immunity to vaccinia only in systemic lymphoid tissue and not in mucosal sites, we hypothesized that the mucosal immune system remains naive to vaccinia and therefore amenable to immunization with recombinant vaccinia vectors despite earlier vaccinia exposure. We show that mucosal immunization of vaccinia-immune BALB/c mice with recombinant vaccinia expressing HIV gp160 induced specific serum antibody and strong HIV-specific cytotoxic T lymphocyte responses. These responses occurred not only in mucosal but also in systemic lymphoid tissue, whereas systemic immunization was ineffective under these circumstances. In this context, intrarectal immunization was more effective than intranasal immunization. Boosting with a second dose of recombinant vaccinia was also more effective via the mucosal route. The systemic HIV-specific cytotoxic T lymphocyte response was enhanced by coadministration of IL-12 at the mucosal site. These results also demonstrate the independent compartmentalization of the mucosal versus systemic immune systems and the asymmetric trafficking of lymphocytes between them. This approach to circumvent previous vaccinia immunity may be useful for induction of protective immunity against infectious diseases and cancer in the sizable populations with preexisting immunity to vaccinia from smallpox vaccination.  (+info)

Other: Comparator: Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine Biological: Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose) Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose) Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose) Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose) Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose) Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose) Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose) Biological: Comparator: Placebo to MRKAd5 HIV-1 gag vaccine ...
INACTIVATION: HIV VACCINE RESEARCH AND DESIGN - R01 GRANTS Release Date: October 4, 1999 PA NUMBER: PA-98-089 National Institute of Allergy and Infectious Diseases The National Institute of Allergy and Infectious Diseases (NIAID) is inactivating program announcement PA 98-089, HIV VACCINE RESEARCH AND DESIGN - RESEARCH PROJECT GRANTS, which appeared in the NIH Guide, July 9, 1998. The areas of investigator-initiated vaccine research this PA targeted have received numerous responses that have been well-received in the NIH peer review system. Accordingly NIAID will no longer give special consideration for funding to applications in response to this PA received after January 2, 2000. NIAID will, however, continue to give special consideration for funding to applications in response to PAR 98-090, HIV VACCINE RESEARCH AND DESIGN - PROGRAM PROJECT GRANTS, which also appeared in the NIH Guide, July 9, 1998. NIAID supports highly scientifically meritorious applications in all areas of research within ...
Prospective cohort study of the clinical course of HIV-1 infection occurring after candidate HIV-1 vaccination (breakthrough infection) with ALVAC-HIV (vcP1521) and AIDSVAX B/E. This study will enroll volunteers who become HIV-infected during the course of follow up in a phase III preventive HIV vaccine trial conducted in Rayong and Chon Buri, Thailand. Volunteers will be enrolled in this protocol to provide additional long-term follow up to establish whether differences in viral load after infection (comparing vaccine to placebo) are associated with altered disease outcomes, as well as provide more detailed immunologic and virologic assessment of these volunteers ...
AIDS Cooperative Adjuvant Groups conduct preclinical studies of adjuvants and vaccine-adjuvant combinations.. AIDS Vaccine Reagent Project provides large quantities of reagents for preclinical and clinical studies related to vaccines.. Antibody Serologic Project identifies and standardizes monoclonal antibodies to characterize specific components of HIV and SIV.. AVEG (AIDS Vaccine Evaluation Group) includes six centers conducting Phase I and II trials of potential HIV vaccines.. AVEU (AIDS Vaccine Evaluation Unit) is an individual clinical site in the AVEG.. Chimpanzee Unit is a site for the evaluation of HIV vaccine concepts and products in chimpanzees.. Cooperative Mucosal Immunology Group for Investigations on AIDS Vaccines examines ways to stimulate and evaluate mucosal immune responses to HIV and SIV infection and vaccines.. DSMB (Data and Safety Monitoring Board) is an independent committee associated with the AVEG that reviews data of trials in progress to ensure that no participant is ...
Jamie Scott, a Simon Fraser University professor and Canada Research Chair in molecular immunity, and three international collaborators are getting a hefty financial boost in their efforts to develop an effective HIV/AIDS vaccine.. The United States National Institutes of Health (NIH) has awarded the four researchers $2.7 million to help them improve the effectiveness of a DNA-based vaccine that Marinieve Montero first conceived of eight years ago. Montero was a student of Scotts whose work was also funded by the NIH, the U.S.s largest government-funded medical research agency.. Scotts current collaborators are at the University of the Basque Country, the University of Massachusetts School of Medicine and the University of California, San Francisco.. The researchers will use their new funding to strengthen a vaccine theyve made from a DNA fragment taken from the HIV genome. The fragment encodes something that is highly prized in HIV/AIDS vaccine research. Called the MPER, its a region of ...
FederalGrants.com opportunity listing for the HIV Vaccine Research and Design (HIVRAD) Program (P01) federal grant. Includes information on eligibility, deadlines, requirements, and guidelines.
BOSTON - More than three decades after the identification of the human immunodeficiency virus (HIV), scientists are still working to develop a preventative vaccine that could finally put an end to the..
Important unanswered questions remain in the development of an effective AIDS vaccine, which could be a decade or more away, a top AIDS Researcher said ...
The massive growth in global health research in past decades has posed many challenges for its effective ethical oversight, not least of which is how best to provide effective protection of research participants. The extent of the HIV epidemic in sub-Saharan Africa in particular makes research into prevention technologies for HIV, including HIV vaccine research, a global priority. However, the need for vaccine research must be considered in conjunction with the individuals right to informed consent, which is based on the principle of respect for autonomy. One of the primary human rights violations likely to occur in the context of HIV vaccine research is that potential research participants may not fully understand what participation in research studies entails. People who elect to enrol in HIV vaccine trials are required to understand both the potential negative effects of participation (eg, discrimination) as well as complex scientific concepts such as randomisation and prophylaxis in order ...
Experimental HIV/AIDS vaccines under development by Merck and Sanofi-Aventis are entering crucial stages, and results from clinical trials for both ...
Background With the persistent challenges towards controlling the HIV epidemic, there is an ongoing need for research into HIV vaccines and drugs. Sub-Saharan African countries - worst affected by the HIV pandemic - have participated in the conduct of clinical trials for HIV vaccines. In Kenya, the Kenya AIDS Vaccine Initiative (KAVI) at the University of Nairobi has conducted HIV vaccine clinical trials since 2001. Methodology Participants were recruited after an extensive informed consent process followed by screening to determine eligibility. Screening included an assessment of risk behavior, medical history and physical examination, and if clinically healthy, laboratory testing. In the absence of locally derived laboratory reference ranges, the ranges used in these trials were derived from populations in the West. Principal findings Two hundred eighty-one participants were screened between 2003 and 2006 for two clinical trials. Of these, 167 (59.4%) met the inclusion/exclusion criteria. Overall,
A year ago, we reported on the push to discover an effective AIDS vaccine. As President Obama prepares to release his U.S. AIDS strategy, at least one pharmaceutical company is readying a crucial clinical trial of its vaccine against HIV/AIDS.. The AIDS Research Consortium of Atlanta recently put out a call for volunteers to test a DNA-based AIDS vaccine developed by GeoVax. Participants must have had a negative HIV test followed by a positive test six months later, and must have started drugs to fight the virus within the past six months. A total of 10 to 12 patients will be enrolled in the Phase I study. Participants will be monitored for up to 77 weeks. Although GeoVax is already testing the vaccine for virus prevention, this will be the first study to test the vaccine in individuals who already have the virus.. Other updates: A lab devoted to developing an HIV/AIDS vaccine has opened in Brooklyn, New York. Researchers at SUNY Downstates Incubator will work with the International AIDS ...
The International AIDS Vaccine Initiative (IAVI) is a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world.
The International AIDS Vaccine Initiative (IAVI) is a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world.
American researchers have come up with a new approach to vaccine design that could help them overcome the difficulties faced in developing an effective HIV vaccine.
To augment the immune responses elicited by these and other vaccines, scientists use immunologic adjuvants. Currently, only one adjuvant -- alum, first discovered in 1926 -- is incorporated into vaccines licensed for human use by the U.S. Food and Drug Administration (FDA). An adjuvant may work well with one experimental vaccine and not another. Therefore, the FDA licenses the vaccine formulation, or the antigen-adjuvant combination, rather than the adjuvant alone. Experimental adjuvants can increase the type, strength and durability of immune responses evoked by an experimental vaccine. For example, some vaccine antigen/adjuvant combinations can induce cell-mediated immune responses, even if the vaccine antigen by itself does not. Some adjuvants also stimulate mucosal immunity. Alum primarily increases the strength of antibody responses generated by the vaccine antigen. Because of its limited activity, other adjuvants may be better suited for the newer candidate HIV vaccines ...
EPALINGES, SWITZERLAND--(Marketwired - April 11, 2016) - Mymetics Corporation (OTCQB:MYMX), a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases across mucosal membranes, announced today that its innovative HIV vaccine candidate has shown to generate significant protection in groups of twelve female monkeys...
Designing an effective HIV/AIDS vaccine is something of a paradox: a good vaccine would be safe and look enough like HIV to kick-start the immune system into neutralizing the virus - but the problem is that this is exactly what the human immune system has trouble doing even when its exposed to the real thing.. Now a team of researchers led by scientists at The Scripps Research Institute in La Jolla, CA has developed a strategy for inducing a key part of an effective immune response to HIV. By tracing the evolution of HIV-recognizing molecules called antibodies taken from the blood of rare individuals whose immune systems are naturally able to target and neutralize the virus, they may have found a way to replicate this for everybody.. At a talk next week at the American Crystallographic Association meeting in Hawaii, the team will present multiple crystal structures, which like detailed architectural blueprints show how the virus interacts with components of the immune system. Examining these ...
Additional research on public and private demand for HIV vaccines is needed to strengthen ongoing advocacy and planning for eventual vaccine introduction, say Hecht and Suraratdecha.
The breakthrough manufacturing technology developed by Vivalis, and now to be further developed through collaboration with GeoVax, will create a new standard for manufacture of the MVA component of the GeoVax HIV/AIDS vaccine, making present manufacturing technologies which have limited production capabilities, less competitive. Vivalis EBx® manufacturing platform, with its increased effectiveness, superior quality and reliability, will speed time to market MVA vaccine product availability in ample quantities to meet sizeable demand and expectedly at a lesser cost ...
A vaccine efficacy trial (known as HVTN 702) in South Africa (started 2016),. The AMP study in the Americas, Europe and Africa (started 2016), and. A vaccine trial (known as HPX2008/HVTN 705) in several African countries (expected to start in 2017/2018). HVTN 702 is testing a vaccine adapted from the one in RV144, while AMP, which stands for Antibody Mediated Prevention, is testing a different approach known as passive immunization. In the AMP study, participants will receive anti-HIV antibodies directly through an intravenous infusion, commonly known as an IV or getting a drip. The findings of the AMP study will advance the HIV vaccine field.. Zimbabwe is part of the global partnership dedicated to HIV vaccine research, and is part of the AMP study.. The University of Zimbabwe-University of California San Francisco Collaborative Research Programme (UZ-UCSF)s Seke South Clinical Research Site (CRS) was selected as a protocol-specific site by the US National Institutes of Healths HIV ...
Sanofi Pasteur announced the results of a Phase 3 trial with its HIV prime vaccine, ALVAC HIV (recombinant canarypox vCP1521) in combination with the booster AidsVax B/E (recombinant gp120 vaccine, from VaxGen).
Researchers hope that this oral vaccine will create a more robust immune response against HIV. We think that an oral approach may be the way to create a more effective vaccine and Im sure that most people would rather get a vaccine in a pill rather than by yet another shot, said Michael C. Keefer, M.D., professor of Medicine and director of the Universitys NIH-supported HIV Vaccine Trials Unit. John J. Treanor, M.D., professor of Medicine and chief of Infectious Diseases at UR Medicines Strong Memorial Hospital is leading the study with support from Keefer, who has more than 20 years of experience in the preventive HIV vaccine field. They will monitor how peoples immune systems respond to the vaccine and if the vaccine causes any symptoms. The University has a long track record of conducting detailed studies of HIV vaccines, but Keefer says that this is the first time an oral vaccine has been tested in Rochester. Though the research is in its early stages, he believes the information ...
Experts at a four-day global HIV/AIDS vaccine conference in Cape Town, South Africa, that opened Monday plan to seek fresh strategies against the ...
NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Center for HIV/AIDS Vaccine Immunology (CHAVI) RFA-AI-04-051. NIAID
A clinical trial testing a candidate HIV vaccine known as the STEP study was halted in September 2007 after interim analysis indicated that the vaccine did not work. Moreover, subsequent analyses indicated that the vaccine made some individuals more susceptible to HIV, in particular individuals who had pre-existing immune effectors (antibodies) that recognized a component of the vaccine (adenovirus serotype 5 [Ad5]).
What can you do to maintain your health at age 65 or older? More than you might think! This article will focus on one aspect of health maintenance: preventive vaccines. Flu vaccine During flu epidemics, the hospitalization rate for older people increases two to five times.
TY - CHAP. T1 - Challenges in designing HIV env immunogens for developing a vaccine. AU - Srivastava, Indresh K.. AU - Holland Cheng, R.. PY - 2008/1/1. Y1 - 2008/1/1. N2 - HIV continues to be a major health problem worldwide; however, the situation is particularly serious in Asian and Sub-Saharan countries. Development of an effective HIV vaccine could help to reduce the severity of the disease and prevent infection. Over the last two decades significant efforts have been made toward inducing potent humoral and cellular immune responses by vaccination; however, it appears that either antibodies or CTL may not be sufficient alone for the induction of sterilizing immunity or long-term control of viral replication. Therefore, it is generally believed that both humoral and cellular responses will be needed for an effective HIV vaccine. It has been shown in passive transfer experiments using broadly neutralizing monoclonal antibodies (mAb) such as b12, 2F5, and 2G12 that these mAbs either alone or ...
New York, September 21, 2007 -- The AIDS Vaccine Advocacy Coalition (AVAC) released the following statement from Executive Director Mitchell Warren about the announcement that vaccinations have been discontinued in the STEP Study, a test-of-concept trial of the MRK-Ad5 AIDS vaccine candidate developed by the Merck Research Laboratories:Todays announcement about the STEP
Global Preventive Vaccines Market - offers growth, outlook, trends, shares, Industry Analysis, opportunities, Key Players Forecast 2018 to 2024
BACKGROUND RV144 is the only preventive HIV vaccine regimen demonstrating efficacy in humans. Attempting to build upon RV144 immune responses, we conducted a phase 1, multicenter, randomized, double-blind trial to assess the safety and immunogenicity of regimens substituting the DNA-HIV-PT123 (DNA) vaccine for ALVAC-HIV in different sequences or combinations with AIDSVAX B/E (protein).METHODS One hundred and four HIV-uninfected participants were randomized to 4 treatment groups (T1, T2, T3, and T4) and received intramuscular injections at 0, 1, 3, and 6 months (M): T1 received protein at M0 and M1 and DNA at M3 and M6; T2 received DNA at M0 and M1 and protein at M3 and M6; T3 received DNA at M0, M1, M3, and M6 with protein coadministered at M3 and M6; and T4 received protein and DNA coadministered at each vaccination visit.RESULTS All regimens were well tolerated. Antibodies binding to gp120 and V1V2 scaffold were observed in 95%-100% of participants in T3 and T4, two weeks after final ...
Recently, the Merck pharmaceutical company reported that its experimental HIV vaccine raised the rate of HIV infection among people who got the trial vaccine. Yes, you read that right. It was worse than nothing. This vaccine was composed of a few HIV proteins strapped onto an adenovirus, which causes colds. Among people with good immunity to this common cold virus, about 80% of the population, it increased the chances of contracting HIV. The saddest part is that this is not surprising. Virologists have long been skeptical about the possibility of an effective HIV vaccine. HIV infects the very immune cells that you stimulate to defend your body against it. Stimulating these cells increases the rate at which HIV can infect those cells and the rate of HIV replication in these cells. Thus, an HIV vaccine can make it more likely that you’ll get AIDS, and you might get it sooner and worse than if you weren’t immunized. So far, no one has found the Holy Grail of HIV vaccines: a ...
BACKGROUND RV144 is the only preventive HIV vaccine regimen demonstrating efficacy in humans. Attempting to build upon RV144 immune responses, we conducted a phase 1, multicenter, randomized, double-blind trial to assess the safety and immunogenicity of regimens substituting the DNA-HIV-PT123 (DNA) vaccine for ALVAC-HIV in different sequences or combinations with AIDSVAX B/E (protein).METHODS One hundred and four HIV-uninfected participants were randomized to 4 treatment groups (T1, T2, T3, and T4) and received intramuscular injections at 0, 1, 3, and 6 months (M): T1 received protein at M0 and M1 and DNA at M3 and M6; T2 received DNA at M0 and M1 and protein at M3 and M6; T3 received DNA at M0, M1, M3, and M6 with protein coadministered at M3 and M6; and T4 received protein and DNA coadministered at each vaccination visit.RESULTS All regimens were well tolerated. Antibodies binding to gp120 and V1V2 scaffold were observed in 95%-100% of participants in T3 and T4, two weeks after final ...
BACKGROUND RV144 is the only preventive HIV vaccine regimen demonstrating efficacy in humans. Attempting to build upon RV144 immune responses, we conducted a phase 1, multicenter, randomized, double-blind trial to assess the safety and immunogenicity of regimens substituting the DNA-HIV-PT123 (DNA) vaccine for ALVAC-HIV in different sequences or combinations with AIDSVAX B/E (protein).METHODS One hundred and four HIV-uninfected participants were randomized to 4 treatment groups (T1, T2, T3, and T4) and received intramuscular injections at 0, 1, 3, and 6 months (M): T1 received protein at M0 and M1 and DNA at M3 and M6; T2 received DNA at M0 and M1 and protein at M3 and M6; T3 received DNA at M0, M1, M3, and M6 with protein coadministered at M3 and M6; and T4 received protein and DNA coadministered at each vaccination visit.RESULTS All regimens were well tolerated. Antibodies binding to gp120 and V1V2 scaffold were observed in 95%-100% of participants in T3 and T4, two weeks after final ...
BACKGROUND RV144 is the only preventive HIV vaccine regimen demonstrating efficacy in humans. Attempting to build upon RV144 immune responses, we conducted a phase 1, multicenter, randomized, double-blind trial to assess the safety and immunogenicity of regimens substituting the DNA-HIV-PT123 (DNA) vaccine for ALVAC-HIV in different sequences or combinations with AIDSVAX B/E (protein).METHODS One hundred and four HIV-uninfected participants were randomized to 4 treatment groups (T1, T2, T3, and T4) and received intramuscular injections at 0, 1, 3, and 6 months (M): T1 received protein at M0 and M1 and DNA at M3 and M6; T2 received DNA at M0 and M1 and protein at M3 and M6; T3 received DNA at M0, M1, M3, and M6 with protein coadministered at M3 and M6; and T4 received protein and DNA coadministered at each vaccination visit.RESULTS All regimens were well tolerated. Antibodies binding to gp120 and V1V2 scaffold were observed in 95%-100% of participants in T3 and T4, two weeks after final ...
A new study by the federal National Institute of Allergy and Infectious Diseases shows that many Americans think a preventive vaccine for HIV already exists and is being kept secret. NIAID surveys showed that 48% of African-American and 28% of Latino respondents believe that such a vaccine has been developed and is being kept from the public. Overall, about 20% of the 3,500 adults surveyed reported believing that a secret vaccine exists. Other widely reported misconceptions include a fear that HIV vaccines can cause HIV infection in clinical trial volunteers.. To help debunk such beliefs, NIAID is sponsoring the sixth annual HIV Vaccine Awareness Day on May 18. The goal of the event is to provide accurate information about HIV/AIDS and HIV vaccine research to the public. HIV vaccine research is our best hope, along with other prevention and treatment efforts, to slow the spread of HIV, said NIAID director Anthony Fauci. NIAID is committed to educating the public to help correct misconceptions ...
The design of an effective AIDS vaccine has eluded the efforts of the scientific community to the point that alternative approaches to classic vaccine formulations have to be considered. We propose here that HIV vaccine research could greatly benefit from the study of natural simian immunodeficiency …
The Picker lab is now investigating the possible reasons why only a subset of the animals treated had a positive response in hopes that the effectiveness of the vaccine candidate can be further boosted.. This research was funded by several grants from the National Institutes of Health, funding from the International AIDS Vaccine Initiative and a CAVD grant from the Bill & Melinda Gates Foundation.. In the interest of ensuring the integrity of our research and as part of our commitment to public transparency, OHSU actively regulates, tracks and manages relationships that our researchers may hold with entities outside of OHSU. In regards to this research project, OHSU has licensed a CMV technology, of which Picker is an inventor, to the International AIDS Vaccine Initiative. In addition, CMV vector technology is being commercialized by TomegaVax, Inc., a company in which both OHSU and Picker have a significant financial interest.. More information on OHSUs conflict of interest policies and ...
ENGLISH ABSTRACT: Background South Africa is the country with the largest number of HIV infections in the world. As behaviour change initiatives have been suboptimal in curbing the spread of the pandemic, an HIV vaccine is likely to be an important development as a biological agent may circumvent some of the challenges of initiating widespread behaviour change. The development of an HIV vaccine will require several thousands of HIV negative participants who are at high risk of HIV infection to participate in HIV vaccine clinical trials. Before recruitment for such trials may begin, various scientific, ethical, and sociobehavioural issues need to be considered. One of the key sociobehavioural issues concerns the willingness of individuals at high risk of HIV infection to participate in HIV vaccine trials. However, a psychometric measure of willingness to participate (WTP) has not been constructed, and there is a paucity of theory to guide studies of WTP. Objectives The first objective of this ...
An independent Data and Safety Monitoring Board (DSMB) met this week to review interim data from a large, international HIV vaccine clinical trial known as the STEP study - also referred to as the HVTN 502 or Merck V520-023 study. The clinical trial, which began enrolling volunteers in December 2004, is co-sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the pharmaceutical company Merck & Co. Inc., which also developed and supplied the candidate vaccine. Based on a review of interim data, the DSMB concluded that the vaccine cannot be shown in this trial to prevent HIV infection or affect the course of the disease in those who become infected with HIV (the vaccine itself cannot cause HIV infection because it contains only synthetically produced snippets of viral material). Therefore, Merck and NIAID instructed all study sites to cease administering the investigational vaccine but continue scheduled follow-up ...
Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap A phase I safety and immunogenicity study investigated South African AIDS Vaccine Initiative (SAAVI) HIV-1 subtype C (HIV-1C) DNA vaccine encoding Gag-RT-Tat-Nef and gp150, boosted with modified vaccinia Ankara…
ROCKVILLE, Md., Oct. 29, 2008 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) announced today positive final results from its Phase 2 NicVAX(r) (Nicotine Conjugate Vaccine) schedule optimization immunogenicity study to assess the antibody response and safety of a 400 microgram, six dose immunization schedule. The vaccine lot used in this study is from the same lot used in the Phase 2b proof-of-concept trial whose results were announced in November 2007. Final results from the study confirmed the positive interim results announced in July that significantly higher anti-nicotine antibody levels can be generated three months earlier and in a much higher percentage of subjects for sustained periods of time than observed in previous NicVAX studies. Antibody levels achieved at 14 weeks were more than 2-fold higher than those achieved at the same time point in the Phase 2b proof-of-concept study as a result of the added injection. Moreover, greater than 80% of subjects who completed the six- ...
OBJECTIVES: Therapeutic HIV vaccinations may alter the size of the resting memory CD4 T-cell latent HIV reservoir as HIV establishes latency when memory responses are formed, including those toward HIV. Alternatively, latently infected CD4 T cells maybe killed, while exiting the reservoir upon activation. METHODS: The effect of therapeutic immunization with modified vaccinia Ankara and Fowlpox-based HIV vaccines on the latent reservoir was examined in 19 young adults who were receiving effective antiretroviral therapy. Correlations between size of the reservoir [measured in infectious units per million (IUPM)] resting CD4 T cells and HIV-specific immune responses, including immune activation were examined. Decay of the reservoir was assessed using random-effects model. RESULTS: A modest transient decrease in the size of the reservoir was observed at week 40 [mean -0.31 log(10) IUPM (95% confidence interval: -0.60 to -0.03; P = 0.03] following HIV vaccinations. The estimated half-life (T1/2) of the
The ALVAC-HIV/AIDSVAX-B/E RV144 vaccine trial showed an estimated efficacy of 31%. RV144 secondary immune correlate analysis demonstrated that the combination of low plasma anti-HIV-1 Env IgA antibodies and high levels of antibody-dependent cellular cytotoxicity (ADCC) inversely correlate with infection risk. One hypothesis is that the observed protection in RV144 is partially due to ADCC-mediating antibodies. We found that the majority (73 to 90%) of a representative group of vaccinees displayed plasma ADCC activity, usually (96.2%) blocked by competition with the C1 region-specific A32 Fab fragment. Using memory B-cell cultures and antigen-specific B-cell sorting, we isolated 23 ADCC-mediating nonclonally related antibodies from 6 vaccine recipients. These antibodies targeted A32-blockable conformational epitopes (n = 19), a non-A32-blockable conformational epitope (n = 1), and the gp120 Env variable loops (n = 3). Fourteen antibodies mediated cross-clade target cell killing. ADCC-mediating ...
During trials of preventive HIV vaccines, trial participants may develop HIV-related antibody responses that could lead to a positive HIV test by routine antibody detection methods (called vaccine-induced seropositivity/reactivity ...
This proposal describes the Harvard Medical School (HMS) Vaccine Clinical Trials Unit (CTU), which is comprised of an administrative component at HMS, two Clini...
Vaccination seems to be the key to curtailing the HIV epidemic but all efforts to make a clinically effective vaccine have failed to date. Eliciting high titres of neutralising antibodies at the mucosal portals of viral entry is a key goal in HIV vaccine research. Thus, this thesis specifically focuses at the strategic development and evaluation of women-controlled mucosal vaccine delivery systems for HIV envelope based constructs, H4A, gp140 and FP-A for the purpose of eliciting high antibody titres at the vaginal mucosa. Sustained release rod-insert vaginal rings (RiRs) loaded with gp140, quick release rods containing H4A, FP-A loaded liposomal gels and microneedles in conjunction with mucosal inoculations were evaluated for induction of specific antibodies in animal models (sheep/mice/rabbits). The formulations were evaluated mainly using vaginal delivery with nasal route being used as an auxiliary. However, we found that the nasal route was extremely potent compared to the vaginal route for ...
HVTN 505 is a preventative vaccine efficacy trial testing DNA followed by recombinant adenovirus serotype 5 (rAd5) in circumcised, Ad5-seronegative men and transgendered persons who have sex with men in the United States. Identified immune correlates of lower HIV-1 risk and a virus sieve analysis revealed that, despite lacking overall efficacy, vaccine-elicited responses exerted pressure on infecting HIV-1 viruses. To interrogate the mechanism of the antibody correlate of HIV-1 risk, we examined antigen-specific antibody recruitment of Fcγ receptors (FcγRs), antibody-dependent cellular phagocytosis (ADCP), and the role of anti-envelope (anti-Env) IgG3. In a prespecified immune correlates analysis, antibody-dependent monocyte phagocytosis and antibody binding to FcγRIIa correlated with decreased HIV-1 risk. Follow-up analyses revealed that anti-Env IgG3 breadth correlated with reduced HIV-1 risk, anti-Env IgA negatively modified infection risk by Fc effector functions, and that vaccine ...
HVTN 505 is a preventative vaccine efficacy trial testing DNA followed by recombinant adenovirus serotype 5 (rAd5) in circumcised, Ad5-seronegative men and transgendered persons who have sex with men in the United States. Identified immune correlates of lower HIV-1 risk and a virus sieve analysis revealed that, despite lacking overall efficacy, vaccine-elicited responses exerted pressure on infecting HIV-1 viruses. To interrogate the mechanism of the antibody correlate of HIV-1 risk, we examined antigen-specific antibody recruitment of Fcγ receptors (FcγRs), antibody-dependent cellular phagocytosis (ADCP), and the role of anti-envelope (anti-Env) IgG3. In a prespecified immune correlates analysis, antibody-dependent monocyte phagocytosis and antibody binding to FcγRIIa correlated with decreased HIV-1 risk. Follow-up analyses revealed that anti-Env IgG3 breadth correlated with reduced HIV-1 risk, anti-Env IgA negatively modified infection risk by Fc effector functions, and that vaccine ...
There is an imperative need for effective preventive vaccines against human cytomegalovirus (HCMV) as it poses a significant threat to the immunologically immature, causing congenital disease, and to the immune compromised including transplant recipients. In this study we examined the efficacy of synthetic long peptides (SLPs) as a CD4+ and CD8+ T cell-eliciting preventive vaccine approach against mouse CMV (MCMV) infection. In addition, the use of agonistic OX40 antibodies to enhance vaccine efficacy was explored. Immunocompetent C57BL/6 mice were vaccinated in a prime-boost vaccination regiment with SLPs comprising various MHC class I and II-restricted peptide epitopes of MCMV-encoded antigens. Enforced OX40 stimulation resulted in superior MCMV-specific CD4+ as CD8+ T cell responses when applied during booster SLP vaccination. Vaccination with a mixture of SLPs containing MHC class II epitopes and OX40 agonistic antibodies resulted in a moderate reduction of the viral titers after challenge with
The discovery of these exceptionally broadly neutralizing antibodies to HIV and the structural analysis that explains how they work are exciting advances that will accelerate our efforts to find a preventive HIV vaccine for global use, says Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health. In addition, the technique the teams used to find the new antibodies represents a novel strategy that could be applied to vaccine design for many other infectious diseases. Led by a team from the NIAID Vaccine Research Center (VRC), the scientists found two naturally occurring, powerful antibodies called VRC01 and VRC02 in an HIV infected individuals blood using a novel molecular device they developed that hones in on the specific cells that make antibodies against HIV. The device is an HIV protein that the scientists modified so it would react only with antibodies specific to the site where the virus binds to cells it ...
The Independent Evaluation Group (IEG) is an independent unit within the World Bank Group charged with objectively evaluating the activities of the International Bank for Reconstruction and Development (IBRD) and International Development Association (IDA; collectively, the World Bank), the work of International Finance Corporation (IFC) in private sector development, and Multilateral Investment Guarantee Agencys (MIGA) guarantee projects and services to provide accountability, and determine what works, what doesnt and why. The head of IEG, the Director-General, Evaluation, reports directly to the Bank Groups Board of Executive Directors and not to Bank Group management. The World Bank Group has twin goals: to end extreme poverty and boost shared prosperity. To achieve these goals, the World Bank Group needs to better understand what works and why, to draw lessons and good practices from experience, deepening the evidence base to inform decision making and future action. IEG evaluations seek ...
The quest for an efficacious HIV vaccine has resulted in several clinical trial failures, including the Step Trial, which used a replication-incompetent adenovirus (AdV) vector called human adenovirus type 5 (HAdV-5). Despite eliciting strong cellular immune responses, these trials were prematurely halted due to statistical futility resulting from increased HIV acquisition in vaccinated individuals. The Step Study showed increased HIV susceptibility in HAdV-5 baseline seropositive subjects, which complicates the use of HAdV-5 vectors since pre-existing neutralizing antibodies (nAb) to HAdV-5 are prevalent worldwide. Sampling the unique immunological phenotypes of the rectal mucosa - the site of HIV infection in the Step Study, and of AdV persistence and trafficking - could help explain this trial, since only peripheral blood (PBMC) was collected from subjects. We obtained rectal lamina propria T lymphocytes (rLPL) from a rhesus macaque (RM) model vaccinated with a species-specific simian Ad type 7 (SAdV
Table 3 shows the results. The hypotheses predict a positive parameter for Ab1 X Cf term and a negative parameter for Cb2 X Cf term. Results support this prediction: The parameter estimate was positive and significant for Ab1 X Cf term (bAb1xCf=.387, t=3.286, p , .01) and negative and significant for Cb2 X Cf term (bCb2xCf= -.325, t= -3.154, p , .01). As expected, the parameter estimate was insignificant for attitude confidence (bCf= -.017, t= -.280). These results support H4-a and H4-b.. Although our major concern was the effect of ad exposure on brand attitudes at a later time, we additionally investigated the effects of Aad1 and Ab1 on Aad2 in each evaluation group. In the ad evaluation group, Aad2 appeared to be influenced by Aad1 more than by Ab1 (.357 vs. -.122), whereas in the brand evaluation group Aad2 appeared to be influenced by Ab1 more than by Aad1 (.605 vs. .046). The reason is thought to be that in the ad evaluation group Aad1 is more salient than Ab1, whereas in the brand ...
TY - JOUR. T1 - Modeling the economic benefits of an AIDS vaccine. AU - Bishai, David. AU - Lin, Maria K.. AU - Kiyonga, C. W.B.. N1 - Funding Information: The authors gratefully acknowledge the suggestions of seminar participants at the World Bank, The Welch Center, and The International Health Economics Association, and UNAIDS. Special thanks are due to Martha Ainsworth, Amie Batson, Stefano Bertozzi, Don Burke, José Esparza, Mark Kane, Bob Lawrence, Richard Mahoney, Philip Musgrove, Ken Nelson, and Tomas Philipson. All errors are our own. Grant support: World Bank (DB, MKL), the Hopkins Population Center, NIH Grant SP30HD06268-25(DB), and the Bill and Melinda Gates Institute for Population and Reproductive Health (CWBK). Copyright: Copyright 2007 Elsevier B.V., All rights reserved.. PY - 2001/11/12. Y1 - 2001/11/12. N2 - Economic models were used to describe the potential for an AIDS vaccine to prevent medical spending and lost productivity throughout the world. In terms of avoided medical ...
There is increasing interest in the use of viral and nonviral systems as vectors to elicit anti-HIV-1 immune responses. The human clinical testing of these vectors can be guided by results of comparative studies in appropriate nonhuman primate immunogenicity and challenge model systems. Recently, we reported on the ability of SIV Gag delivered by DNA, MVA, or adenovirus type 5 vectors to inhibit viral replication and disease progression in rhesus macaques following challenge with SHIV89.6P (25). The best degree of viremia control and CD4 cell count preservation was observed in animals that had been immunized with the adenovirus type 5 vector either by itself or in a prime-boost combination with DNA. In contrast, only 50% of the animals that received MVA alone or in combination with DNA were able to effectively control viremia.. In this report, we evaluated the cellular immune responses to HIV-1 Gag induced by similar DNA, MVA, and adenovirus vectors. The studies were conducted with macaques that ...
TY - JOUR. T1 - Corrigendum to The Starting Treatment for Ethanol in Primary care Trials (STEP Trials). T2 - Protocol for three parallel multi-site stepped care effectiveness studies for unhealthy alcohol use in HIV-positive patients (Contemp. Clin. Trials (2017) 52 (80-90) (S1551714416302130) (10.1016/j.cct.2016.11.008)). AU - Edelman, E. Jennifer. AU - Maisto, Stephen A.. AU - Hansen, Nathan B.. AU - Cutter, Christopher J.. AU - Dziura, James. AU - Fiellin, Lynn E.. AU - OConnor, Patrick G.. AU - Bedimo, Roger. AU - Gibert, Cynthia. AU - Marconi, Vincent C.. AU - Rimland, David. AU - Rodriguez-Barradas, Maria C.. AU - Simberkoff, Michael S.. AU - Justice, Amy C.. AU - Bryant, Kendall J.. AU - Fiellin, David A.. N1 - Publisher Copyright: © 2017. PY - 2017/9. Y1 - 2017/9. N2 - The authors regret that there was an error in the description of the randomization procedures previously published in the manuscript. Randomization is stratified based only on site.. AB - The authors regret that there ...
The death of three monkeys that had been administered an AIDS vaccine in a Boston lab suggests that vaccines intended to prime the immune system to control HIV in the body and prevent disease progression may not offer total protection from AIDS. Numerous HIV vaccines in development aim to boost the bodys defenses to hold the virus in check, with animal studies to date suggesting that the protection offered by the vaccines could last for years, if not indefinitely. However, researchers at the 10th annual Conference on Retroviruses and Opportunistic Infections in Boston on Wednesday reported that three of four monkeys involved in such a study at Beth Israel Deaconess Medical Center in Boston eventually fell sick and died, even after initially showing strong resistance to the virus. All three died within three years of receiving the experimental vaccine developed by Merck.. Researchers were split on their opinions of the Merck vaccine data. David Ho, scientific director of the Aaron Diamond AIDS ...
Glenda E. Gray, M.B., B.Ch., from the Fred Hutchinson Cancer Research Center in Seattle, and colleagues randomly assigned 5,404 adults (median age, 24 years; 70 percent women) without HIV-1 infection to receive canarypox-protein HIV vaccine or placebo (2,704 and 2,700 participants, respectively) in a phase 2b-3 trial in South Africa. The vaccine regimen included injections of ALVAC-HIV at months 0 and 1 followed by ALVAC-HIV plus bivalent subtype C gp120-MF59 adjuvant booster injections at months 3, 6, 12, and 18.. The researchers found that at an interim analysis in January 2020, prespecified criteria for nonefficacy were met, and further vaccinations were subsequently halted. There was a similar incidence of adverse events in the vaccine and placebo groups. HIV-1 infection was diagnosed in 138 and 133 participants in the vaccine and placebo groups, respectively, during the 24-month follow-up (hazard ratio, 1.02; 95 percent confidence interval, 0.81 to 1.30; P = 0.84).. Despite promising ...
HIV vaccines were not part of the main stage at the Durban Aids Conference held in 2000. Our knowledge and experience in HIV vaccine development were rudimentary at this time; our journey to understanding the complexity of designing immunogens to elicit effective immune responses was just beginning. But HIV vaccines are a now pivotal part of the prevention research agenda: there is scientific optimism about the ability to develop an effective vaccine and South Africa is now a central point in this research. The intervening 16 years between the Durban conferences has brought a series of hard-won understandings about how HIV works in orchestrating its transmission from person to person and between communities. Our past approaches to vaccine development have largely been ineffective because the viruss exterior coating, what we call its envelope structure, has areas of immune dampening. In these areas, immune decoys are set up and evolve so cleverly that the initial, critical antibodies that are made to
Synthesis and Vaccine Evaluation of the Tumor Associated Carbohydrate Antigen RM2 from Prostate Cancer : This thesis focuses on the synthesis and vaccine evaluation of the prostate tumor- associated carbohydrate antigen RM2. The author first presents the use of the [1+2+3] one-pot sequential strategy to successfully synthesise the RM2 antigen and its analogues as single stereoisomers in every glycosylation step, producing good yields and stereoselectivity. He then introduces the conjugation of the
... ATLANTA Feb. 25 /- GeoVax Labs Inc. (OTC...GeoVaxs AIDS vaccine is believed to be only the fifth [5th] HIV/AIDS...Most recently GeoVax Senior Vice President of Research & Development...Attended by over 20 HVTN personnel and key GeoVax personnel this even...,GeoVax,Vaccine,Only,5th,AIDS,Vaccine,Moving,to,Phase,2,Human,Trials,medicine,advanced medical technology,medical laboratory technology,medical device technology,latest medical technology,Health
Image Credit: Thinkstock.com. September 11, 2013 Brett Smith for redOrbit.com - Your Universe Online A promising new AIDS vaccine being developed at Oregon Health & Science University has demonstrated the capacity to effectively remove all traces of an AIDS-causing virus from non-human primates, according to a newly published report in the journal Nature. The vaccine is being tested on a primate form of HIV, called simian immunodeficiency virus (SIV), which causes AIDS in monkeys. After working further to refine the vaccine, OHSU scientists said they hoped an HIV-form of the potential vaccine could soon be tested in human subjects. To date, HIV infection has only been cured in a very small number of highly-publicized but unusual clinical cases in which HIV-infected individuals were treated with anti-viral medicines very early after the onset of infection or received a stem cell transplant to combat cancer, said Dr. Louis Picker, associate director of the OHSU Vaccine and Gene Therapy ...
International AIDS Vaccine Initiative. [1] accessed Dec 2007. Archived October 9, 2006, at the Wayback Machine. Poropatich, ... AIDS. 20 (5): 685-9. doi:10.1097/01.aids.0000216368.23325.bc. PMID 16514298. Thorven M, Grahn A, Hedlund KO, Johansson H, ... "Mitochondrial DNA haplogroups influence AIDS progression". AIDS. 22 (18): 2429-2439. doi:10.1097/QAD.0b013e32831940bb. ISSN ... Without the symptoms of AIDS, many LTNP patients may not know they are infected. Genetic traits that confer greater resistance ...
"Center for HIV/AIDS Vaccine Immunology & Immunogen Discovery". scripps.edu.. *^ "Scripps Center for Metabolomics and Mass ...
Bourinbaiar, Aldar S.; Metadilogkul, Orapun; Jirathitikal, Vichai (2003). "Mucosal AIDS Vaccines". Viral Immunology. 16 (4): ... the mucosal immune system is being investigated for use in vaccines for various afflictions, including AIDS and allergies. ... "Recent progress in HIV vaccines inducing mucosal immune responses". AIDS. 28 (12): 1701-18. doi:10.1097/qad.0000000000000308. ... Mucosal Immunity and Vaccines, August 2003 Pavot, V; Rochereau, N; Lawrence, P; Girard, MP; Genin, C; Verrier, B; Paul, S (31 ...
"AIDS vaccine research in Asia: needs and opportunities". AIDS. 13 (11): 1-13. July 1999. doi:10.1097/00002030-199907300-00020. ... UNDP HIV & Development Project, South and Southwest Asia (8 June 2001). National Consultation on HIV/AIDS and the media (PDF). ... Public Health Advocacy for HIV/AIDS. Swarup Sarkar is an Indian epidemiologist, public health professional and diplomat known ... "Is AIDS Financing dying in Asia ? Swarup Sarkar Senior Adviser, UNAIDS, Geneva ICAAP, Busan, August ppt download". Retrieved 16 ...
The St Stephen's Centre is also home to the core laboratory of the International AIDS Vaccine Initiative (IAVI).[13] ... "New partnership to accelerate AIDS vaccine testing, equip developing countries for trials". 13 December 2001. Retrieved 20 ... "Unique partnership brings new hope for vaccine to combat HIV". 1 December 2001. Retrieved 20 April 2018.. ...
Makgoba MW (May 2002). "Politics, the media and science in HIV/AIDS: the peril of pseudoscience". Vaccine. 20 (15): 1899-904. ... The anti-vaccine movement has persuaded large number of parents not to vaccinate their children, citing pseudoscientific ... doi:10.1002/(SICI)1098-237X(199806)82:3,407::AID-SCE6,3.0.CO;2-G.. (subscription required) ... Antivaccine activists present pseudoscientific studies that falsely call into question the safety of vaccines. Homeopathic ...
Trafton, Anne (4 February 2009). "Alum's $100 million gift targets AIDS vaccines". Archived from the original on 2009-02-05. ... In 2009, Ragon pledged to donate US $100 million over 10 years period for AIDS research through the Phillip T. and Susan M. ... "Businessman donates $100 million to AIDS research". Reuters. 4 February 2009. Retrieved 2020-11-23. "Mass General Receives $200 ... 200 million to Massachusetts General Hospital for a vaccine-research center. "Phillip and Susan Ragon Foundation: Grants for ...
... where he would lead the first human trial on the AIDS vaccine. The results of the trial found that the two experimental AIDS ... "New experiment with AIDS vaccines called encouraging". The Sacramento Bee. June 22, 1991. Retrieved January 10, 2021 - via ... "First human tests of AIDS vaccine slated". Auburn Journal. August 12, 1987. Retrieved January 10, 2021 - via newspapers.com. " ... In 2000, the National Institutes of Health (NIH) recruited Graham to create a vaccine-evaluation clinic (Vaccine Research ...
Inc A Killed-Virus Vaccine for HIV/AIDS DID SCIENCE MISS ITS BEST SHOT AT AN AIDS VACCINE? IAVI Report on Whole Killed AIDS ... The International AIDS Vaccine Research (IAVA) issued a report on "Whole Killed AIDS Vaccines" in 1999 reviewing a diverse ... Chil-yong Kang's Lab Killed HIV Vaccine Advocate Phase I Trial Details IAVI Report: Whole Killed AIDS Vaccines US Patent: HIV ... 2] New HIV Vaccine Proves Successful In Phase 1 Human Trial Canadian HIV Vaccine Pushes Through Trials Promising vaccine ...
Merck have tested the a few vaccines and some of the other proposals are being tested by International AIDS Vaccine Initiative ... and International AIDS Vaccine Initiative for the development of HIV vaccines. He has also mentored a number of scholars in ... International AIDS Vaccine Initiative. 2 May 2007. Retrieved 19 October 2016. "Seminar by Prof. Raghavan Varadarajan". ... his team developed a number of immunogens which have been demonstrated to have positive effect as HIV-1 vaccines and he holds ...
Newsletter on International Aids Vaccine Research. International AIDS Vaccine Initiative. 18 (3): 14-7. PMID 25401194. Plaza, ... A brave new world for human vaccine development". Human Vaccines. 5 (12): 790-793. doi:10.4161/hv.10683. PMC 2919815. PMID ... Human Vaccines & Immunotherapeutics. 14 (9): 2214-2216. doi:10.1080/21645515.2018.1476813. PMID 6183335. "The Human Vaccines ... The development of vaccines is also an application of immunome study as shown by Carlos F. Suárez and his colleagues. They were ...
"Building a better vaccine Hildegund Ertl and her Philadelphia researchers pursue a new way to conquer the AIDS virus, threats ... human papilloma virus vaccines, rabies vaccine models, universal influenza vaccine, vaccines to Epstein-Barr virus, and using ... Her research is focused on developing vaccines for AIDS and various forms of cancer. Her lab is currently working on projects ... In interviews, Ertl has been cautious and critical when it comes to the development of vaccines for AIDS. Her research has ...
Vaccines are being researched for AIDS and tuberculosis. Genes associated with type 1 diabetes and certain types of cancer have ...
... "oral polio vaccine AIDS hypothesis", which posited that the AIDS pandemic originated from live polio vaccines such as ... Albert Sabin Discredited HIV/AIDS origins theories Jonas Salk List of Polish people Poles Polio vaccine Wistar Institute ... 119-130 online Archived 2008-08-02 at the Wayback Machine Hilary Koprowski (1992). "AIDS and the polio vaccine". Science. 257 ( ... "Origin of AIDS: contaminated polio vaccine theory refuted" (PDF file, direct download 203 KB). Nature. 428 (6985): 820. doi: ...
In 2018 she was elected to the board of the International AIDS Vaccine Initiative. She is concerned about Donald Trump ... "Board of Directors". IAVI - International AIDS Vaccine Initiative. Retrieved 2018-05-28. "Plenary Sessions - HIVR4P 2018". ... In 2016 she was elected President of the International AIDS Society. She gave the opening address at the International AIDS ... She saw young people dying from HIV/AIDS and was frustrated that she couldn't help them. Her PhD was funded by the John E. ...
Martin, Richard, "Testing the First AIDS Vaccine", Wired Magazine, January 2003. H. Foege, William, House on Fire: The Fight to ... Francis began his work on AIDS in 1981. He was one of the first scientists to suggest that AIDS was caused by an infectious ... to continue working on vaccines. After the vaccine failed in clinical trials, Francis left VaxGen in 2004 to co-found Global ... In 1993, HBO produced And The Band Played On, an Emmy-winning movie about the AIDS crisis based on the 1987 book of the same ...
... particularly in the prevention of hepatitis and AIDS. Gust, Ian D.; Kahn, Patricia; Koff, Wayne C. (2007). AIDS Vaccine ... Gust's area of work is in the development of drugs and vaccines against viral diseases and he is best known for the development ... "Professor Ian Gust". Vaccine and Immunotherapy Technologies. Sir Mark Oliphant Conferences. 2008. Archived from the original on ... The most cited are: Gust, I.D. "Epidemiological patterns of hepatitis A in different parts of the world" (1992) Vaccine, 10 ( ...
Kendall, Don (June 20, 1981). "Vaccine to aid human, animal diseases". Nashua Telegraph. Associated Press. Retrieved June 2, ... This vaccine was the first one developed using genetic engineering. Bachrach retired in 1981. In 1982, he was elected to ... In turn, the bacterium produced a large amount of VP3, and the Bachrach team felt that this could lead to a vaccine against the ... The development of the foot-and-mouth disease vaccine, which was only effective against a single strain of the illness, taught ...
AVAC (January 27, 2015). "News from the HC-HIV front: it's raining meta (analyses)!". New York: AIDS Vaccine Advocacy Coalition ...
"Live attenuated influenza virus vaccines by computer-aided rational design". Nat. Biotechnol. 28: 723-727. doi:10.1038/nbt.1636 ... This strategy allows for the generation of new vaccines in a very short time. Recently, Wimmer's lab has elucidated the key ... synthetic biology has led to a new kind of RNA virus genetics and has been used to develop rapid methods for computer-aided ...
An Expert on AIDS Vaccines". The New York Times. Retrieved July 18, 2014. CS1 maint: discouraged parameter (link) "Founder - ... She was a member of the US Centers for Disease Control Advisory Committee on the Children's Vaccine Initiative and the World ... Mary Lou Clements-Mann (September 17, 1946 - September 2, 1998) was the longtime head of the Division of Vaccine Sciences at ... During this time, she joined the university's Center for Vaccine Development. She later became the chief of the clinical ...
Other examples include experimental AIDS, cancer and Alzheimer's disease vaccines. Such immunizations aim to trigger an immune ... The term "vaccine failure" does not necessarily imply that the vaccine is defective. Most vaccine failures are simply from ... U.S. government Vaccine Research Center: Information regarding preventive vaccine research studies The Vaccine Page links to ... doi:10.1016/j.vaccine.2011.09.124. PMID 22001122. "Thimerosal in Vaccines Thimerosal , Concerns , Vaccine Safety , CDC". www. ...
"Japanese Aid to Boost Safe Vaccine Delivery". Cambodianess. Retrieved 1 April 2021. "Experts Fear Coronavirus Going Undetected ... "More vaccine relief: 700,000 doses of Sinopharm vaccine arrive from China". Khmer Times. Retrieved 1 April 2021. Staff, Reuters ... People above 60 were urged to receive this vaccine, otherwise, Sinopharm vaccine was still for younger ones. 1.5 million ... This is one of the biggest aid from Vietnam to another countries in prevention against COVID-19. On 21 May 2021, Cambodia ...
AIDS Activism and Coronavirus Vaccine Challenge Trials. AIDS and Behavior, 2020. Eyal N, Lipsitch M, Smith PG. Human challenge ... 2017;43:74-7. Eyal N. Why Challenge Trials of SARS‐CoV‐2 Vaccines Could Be Ethical Despite Risk of Severe Adverse Events. ... The New England journal of medicine 2020:382 Eyal N, Lipsitch M. Ethical Comparators in Coronavirus Vaccine Trials. Eyal N, ... Why_continuing_uncertainties_are_no_reason_to_postpone_challenge_trials_for_coronavirus_vaccines. Journal of Medical Ethics. ...
Walker, Bruce, AIDS Vaccine Induces HIV-specific Immune Response In Chronic Infection, Massachusetts General Hospital, ... "Jonas Salk's Quest for an AIDS Vaccine." Village Voice. October 23, 1990 Vol XXXV No. 43. verification: University of ... The end point was slowing the progression to AIDS or death for patients having CD4 T-cells between 300 and 549 cells/mm. Bruce ... Landmark' cancer vaccine gets FDA approval". CNN. Retrieved 2018-10-18. "Sipuleucel-T". Drugs in R & D. 7 (3): 197-201. 2006. ...
"HGP-30 AIDS VACCINE SAFE IN TRIAL". BioWorld. Clarivate. December 3, 1992. Retrieved 21 Feb 2020. "HIV HGP-30W vaccine (Cel-Sci ... "test approval sends aids drug company stocks higher". Newspapers.com. Retrieved 2020-03-20. "CEL-SCI buys rights to new ... "New Vaccine in the Treatment of Rheumatoid Arthritis". BioSpectrum Asia. Singapore: MM ACTIV. July 9, 2019. Retrieved 11 March ... HGP-30 is also being tested to determine if it is an effective treatment against the AIDS virus. In 1996, The Washington Post ...
AIDS vaccine- Washington, Seattle 2007, :P05-01. Wayengera, M (2007). "PREX-1979: Modeling the first ever prototype of could be ... It is also hoped that, when applied to non-HIV infected persons, this strategy could offer a genomic vaccine against HIV and ... Stone, D.; Kiem, H. P.; Jerome, K. R. (2013). "Targeted gene disruption to cure HIV". Curr Opin HIV AIDS. 8 (3): 217-23. doi: ... Alkhatib, G (2009). "The biology of CCR5 and CXCR4". Current Opinion in HIV and AIDS. 4 (2): 96-103. doi:10.1097/coh. ...
2010). "Live attenuated influenza virus vaccines by computer-aided rational design". Nature Biotechnology. 28 (7): 723-6. doi: ... he has worked to computationally design synthetic viruses for use as attenuated vaccines. Their Synthetic Attenuated Virus ...
"AIDS Vaccine Research Offers New Insights On Survival". Medical News Today, June 13, 2006. Retrieved January 12, 2011. Elshtain ... About 50 percent of all Duke students receive some form of financial aid, which includes need-based aid, athletic aid, and ... Reports of Duke researchers' involvement in new AIDS vaccine research surfaced in June 2006. The biology department combines ... Financial Aid Statistics Archived May 6, 2011, at the Wayback Machine . Duke Financial Aid. Retrieved May 3, 2011. Medical ...
... announced that they would start a comprehensive AIDS research program. They started a laboratory dedicated to AIDS research in ... AIDS Clinical Trials Group 320 Study Team". The New England Journal of Medicine. 337 (11): 725-33. doi:10.1056/ ... Indinavir does not cure HIV/AIDS, but it can extend the length of a person's life for several years by slowing the progression ... From then on, indinavir used with dual NRTIs set a new standard for treatment of HIV/AIDS. Protease inhibitors changed the ...
HIV/AIDS denialism *OPV AIDS hypothesis. *Anti-vaccination *Vaccines and autism. *MMR vaccine and autism ... Vaccine. 20 (Suppl 1): S89-93. doi:10.1016/S0264-410X(01)00290-0. PMID 11587822.. ...
Oxford-AstraZeneca vaccine *Post-vaccination embolic and thrombotic events. *European Commission-AstraZeneca COVID-19 vaccine ... Federal aid during the COVID-19 pandemic in Canada. *vaccination *by province ...
Vaccines. Main article: Ebola vaccine. An Ebola vaccine, rVSV-ZEBOV, was approved in the United States in December 2019.[8] It ... Urging the world to offer aid to the affected regions, its Director-General said, "Countries affected to date simply do not ... The DRC Ministry of Public Health approved the use of an experimental vaccine.[207][208][209] On 13 May 2018, WHO Director- ... "First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health ...
Ensnared by AIDS: Cultural Contexts of HIV/AIDS in Nepal. Kathmandu, Nepal: Mandala Book Point. Karki, Yagya B.; Agrawal, ... Two more vaccines were introduced in between 2014 and 2015 ; Inactivated poliomyelitis vaccine (IPV) and Pneumococcal conjugate ... One percent of children in Nepal have not yet received any of the vaccine coverage. The Community-Based Integrated Management ... The government has provided all vaccines and immunization related logistics without any cost to hospitals, the private ...
Infections: HIV-AIDS, Measles, RSV, othersEdit. The role of SP in HIV-AIDS has been well-documented.[58] Doses of aprepitant ... "Clinical and Vaccine Immunology. 13 (11): 1197-203. doi:10.1128/CVI.00174-06. PMC 1656550 . PMID 16971517.. ... and infections such as HIV/AIDS and respiratory syncytial virus,[54] as well as in cancer.[55][56] When assayed in the human, ...
Lunzen, J.; Fehse, B.; Hauber, J. (2011). "Gene Therapy Strategies: Can We Eradicate HIV?". Current HIV/AIDS Reports. 8 (2): 78 ... For this reason transplant patients must be re-vaccinated with childhood vaccines once they are off immunosuppressive ...
The modern era really began with Edward Jenner's discovery of the smallpox vaccine at the end of the 18th century (inspired by ... Medical equipment - Equipment designed to aid in the diagnosis, monitoring or treatment of medical conditions ... Vaccines were discovered by Edward Jenner and Louis Pasteur. ... thus aiding identification.. *Gender-based medicine studies the ...
Vaccines have been formulated and approved for prevention of Lyme disease in dogs. Currently, three Lyme disease vaccines are ... The spread of B. burgdorferi is aided by the attachment of the host protease plasmin to the surface of the spirochete.[87] ... Poland GA, Jacobson RM (March 2001). "The prevention of Lyme disease with vaccine". Vaccine. 19 (17-19): 2303-8. doi:10.1016/ ... "Sole Lyme Vaccine Is Pulled Off Market". The New York Times. 28 February 2002. Archived from the original on 30 August 2010. ...
Anti-vaccine movement. *Vaccines causing autism. *GMO conspiracy theories. *HIV/AIDS origins ... Vaccine. 34 (38): 4484-4500. doi:10.1016/j.vaccine.2016.07.026. ISSN 0264-410X. PMID 27475472.. ... doi:10.1016/j.vaccine.2004.05.027. PMID 15530683.. *^ Jones RB, Mormann DN, Durtsche TB (1989). "Fluoridation referendum in La ... Further information: Vaccine controversy § Alternative medicine, and Water fluoridation controversy. Some chiropractors oppose ...
Aid increased significantly when the Indian Army took control of aid in October 1943, but effective relief arrived only after a ... A similar smallpox vaccine campaign started later and was pursued less effectively;[229] smallpox deaths peaked in April 1944.[ ... To aid the rest of India in their domestic food purchases, the Government of India placed price controls on Punjabi wheat. The ... Humanitarian aid was ineffective through the worst months of the food crisis, and the government never formally declared a ...
"Pneumonia Can Be Prevented - Vaccines Can Help". Centers for Disease Control and Prevention. Nakuha noong 22 October 2012.. ... Ang wastong paggamot ng nasa ilalim na mga karamdaman (tulad ng HIV/AIDS, diabetes mellitus, at malnutrisyon) ay maaaring ... WHO (1999). "Pneumococcal vaccines. WHO position paper". Wkly. Epidemiol. Rec. 74 (23): 177-83. PMID 10437429.. ... 1993). "Decline of childhood Haemophilus influenzae type B (Hib) disease in the Hib vaccine era". JAMA. 269 (2): 221-6. doi: ...
This test can aid in the detection of Aspergillus, Candida, and Pneumocystis jirovecii.[26][27][28] This test cannot be used to ... implications for microbial attachment and oral vaccine targeting". The Journal of Experimental Medicine. 184 (3): 1045-1059. ... "Multicenter clinical evaluation of the (1→3)β-D-glucan assay as an aid to diagnosis of fungal infections in humans". Clin ... "Multicenter clinical evaluation of the (1→3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans" ...
... and HIV/AIDS through needlestick injuries or contact with bodily fluids.[19][20] This risk can be mitigated with vaccination ... when there is a vaccine available, like with hepatitis B.[20] In epidemic situations, such as the 2014-2016 West African Ebola ...
An R, Tang Y, Chen L, Cai H, et al «Encephalitis is mediated by ROP18 of Toxoplasma gondii, a severe pathogen in AIDS patients ... Verma R, Khanna P «Development of Toxoplasma gondii vaccine: A global challenge» (en anglès). Hum Vaccin Immunother, 2013 Feb; ... Bach MC, Skarulis GJ «Acute Toxoplasmic Meningitis in a Patient with AIDS» (en anglès). Clin Infect Dis, 1997 Des; 25 (6), pp: ... Li ZY, Lu J, Zhang NZ, Chen J, Zhu XQ «Immune Responses Induced by HSP60 DNA Vaccine against Toxoplasma gondii Infection in ...
However, newer techniques aid in the definitive identification of the pathogen, which may lead to more individualized treatment ... as the decrease of occult pneumonia after vaccination of children with a pneumococcal vaccine suggests. Infiltration commonly ...
"High HIV-1 genetic diversity in Cuba AIDS 2002". Official Journal of the International AIDS society.. ... Cuba vaccine deal breaks embargo, BBC, July 29, 1999 *^ William Ventres (February 2012). "Book Review: Caring for Them From ... Cuba also successfully exports many medical products, such as vaccines.[63] Health tourism[edit]. Cuba attracts about 20,000[64 ... "UNAIDS/WHO AIDS epidemic update: December 2005. UNAIDS. Retrieved 30 April 2011.. ...
Can repeated plasma donation by asymptomatic HIV-infected individuals delay the onset of AIDS? Phil. Trans. R. Soc. London. B, ... Pandemic influenza preparedness : the critical role of the syringe.. Vaccine. 2006 May 29;24(22):4874-82. Epub 2006 March 20. K ... International Journal of STD & AIDS, 1996:288-291. F. Bouscarat, M. Levacher, M Dazza, K. Strauss, P. Girard, C. Ruggeri, M. ... In Janossy G, Autran B. Miedema F (eds): Immunodefiency in HIV Infection and AIDS, Karger Publishers, Basel, 1992:185-194. D. ...
The AIDS Show - AIDS Vaccine 200 - AIDS Vaccine Advocacy Coalition - AIDS wasting syndrome - AIDS-related cancer - AIDS-related ... AIDS - AIDS Arms - AIDS dementia complex (ADC) - AIDS Drug Assistance Programs (ADAP) - AIDS education and training centers ( ... AETC) - AIDS orphan - AIDS research advisory committee (ARAC) - AIDS service organization (ASO) - ... monovalent vaccine - morbidity - MRI - mucocutaneous - mucosa - mucosal immunity - mucous membrane - Multicenter AIDS Cohort ...
... including HIV/AIDS and tuberculosis.[9] Respiratory infections such as pneumonia do not appear to increase the risk of COPD, at ... A review of an oral Haemophilus influenzae vaccine found 1.6 exacerbations per year as opposed to a baseline of 2.1 in those ... "Influenza vaccine for chronic obstructive pulmonary disease (COPD)". The Cochrane Database of Systematic Reviews. 6: CD002733 ...
MMR vaccine. *Thiomersal (Chelation). Diagnostic scales. *Gilliam Asperger's disorder scale. *Autism Diagnostic Observation ...
Researchers are currently focusing on the development of various vaccines against many diseases including AIDS, malaria, dengue ... In 1985, the first human vaccine obtained by genetic engineering from animal cells, the vaccine against hepatitis B, was ... Chantemesse's typhoid vaccineEdit. During the summer of 1900, the extremely hot weather and scarcity of the water supply in ... Vaccines and Diagnostic ProductsEdit. Production and marketing of diagnostic tests developed in the Institute laboratories are ...
Chaves SS, Gargiullo P, Zhang JX, et al. (2007). "Loss of vaccine-induced immunity to varicella over time". N Engl J Med 356 ( ... doi:10.1002/(SICI)1096-9071(199612)50:4,289::AID-JMV2,3.0.CO;2-4. பப்மெட்:8950684. ... "Chickenpox (Varicella) Vaccine". Immunization Action Coalition (October 2005). பார்த்த நாள் 2006-06-12. ...
Use in vaccinesEdit. The first vaccine against smallpox by Edward Jenner in 1800 was by infection of a zoonotic bovine virus ... Marx PA, Apetrei C, Drucker E (October 2004). "AIDS as a zoonosis? Confusion over the origin of the virus and the origin of the ... and is an important opportunistic pathogen in people immunocompromised by HIV/AIDS, organ transplantation, or CD4+ T-lymphocyte ...
... delivering vaccines to several parts of the world and joining combat forces. In 2000 the bank announced a "war on AIDS" and in ... Combat HIV/AIDS, Malaria, and Other Diseases: Annual numbers of new HIV infections and AIDS deaths have fallen, but the number ... Forty-five countries pledged US$25.1 billion in "aid for the world's poorest countries", aid that goes to the World Bank ... Mosley, Paul; Harrigan, Jane; Toye, John (1995). Aid and Power: The World Bank and Policy Based Lending, 2nd Edition. 1. ...
Anti-vaccine movement. *Vaccines causing autism. *GMO conspiracy theories. *HIV/AIDS origins ...
Anti-vaccine movement. *Vaccines causing autism. *GMO conspiracy theories. *HIV/AIDS origins ...
The scientific approach to food and nutrition arose with attention to agricultural chemistry in the works of J. G. Wallerius, Humphry Davy, and others. For example, Davy published Elements of Agricultural Chemistry, in a Course of Lectures for the Board of Agriculture (1813) in the United Kingdom which would serve as a foundation for the profession worldwide, going into a fifth edition. Earlier work included that by Carl Wilhelm Scheele who isolated malic acid from apples in 1785. In 1874 the Society of Public Analysts was formed, with the aim of applying analytical methods to the benefit of the public.[3] Its early experiments were based on bread, milk and wine. It was also out of concern for the quality of the food supply, mainly food adulteration and contamination issues that would first stem from intentional contamination to later with chemical food additives by the 1950s. The development of colleges and universities worldwide, most notably in the United States, would expand food chemistry ...
doi:10.1016/j.vaccine.2004.10.038. பப்மெட் 15705467. *↑ "Oral Polio Vaccine and HIV / AIDS: Questions and Answers". Centers for ... Physicians AIDS Care (Chic Ill) 1 (2): 53-62. பப்மெட் 12942677. *↑ Pollok RC (2001). "Viruses causing diarrhoea in AIDS". ... 2004). "Origin of AIDS: contaminated polio vaccine theory refuted". Nature 428 (6985): 820. doi:10.1038/428820a. பப்மெட் ... 142.0 142.1 Greener R (2002). "AIDS and macroeconomic impact". in S, Forsyth (ed.). State of The Art: AIDS and Economics. IAEN ...
Shown to be safe in humans, the candidate vaccine has now advanced to the next phase of the pre-approval ... The near 40-year quest for an AIDS vaccine received a hopeful boost Saturday when scientists announced that a trial drug ... Paris (AFP) - The near 40-year quest for an AIDS vaccine received a hopeful boost Saturday when scientists announced that a ... Jean-Daniel Lelievre of Frances Vaccine Research Institute said the vaccine was likely not the "definitive" version, but may ...
The NIAID AIDS Vaccine Clinical Trials Network includes the following:. * The AIDS Vaccine Evaluation Units (AVEUs) [known ... The NIAID AIDS Vaccine Clinical Trials Network is the largest cooperative HIV vaccine clinical trials group in the United ... This fact sheet summarizes NIAIDs approach to developing an HIV/AIDS vaccine. It describes the challenges facing vaccine ... the efficacy of candidate HIV vaccines in U.S. populations.. * An international HIV/AIDS vaccine efficacy trials master ...
Human body test, or stage I clinical test, of the compound AIDS vaccine aims to further assess the security of the vaccine, an ... Chinese AIDS vaccine tested by human body. (Agencies). Updated: 2004-11-26 13:01 ... According to experts, AIDS vaccine is the only solution to stop the wildfire spread of the grievous infectious disease. ... Chinese-developed AIDS vaccine has won government approval to be tested by human bodies, Xinhua reported Friday quoting sources ...
Emorys AIDS vaccine consists of two components: a DNA prime and a recombinant poxvirus as a booster. The vaccine is designed ... Center for manufacture of the vaccine. By late 2004, the Vaccine Center hopes to begin a Phase I trial of a trivalent vaccine ... Robinson projects that Phase III efficacy trials of the AIDS vaccine could begin in 2006. Unlike the much smaller Phase I and ... A California biotech company, ViCal, manufactured the priming components of the AIDS vaccine for the Phase I clinical trial ...
Although AIDS (Acquired Immune Deficiency Syndrome) seems to have appeared full-blown early in this decade, it is not without ... a vaccine is the best bet in the medical rush to stop AIDS from spreading. Yet the possibility of a vaccine presents a new set ... These men are an appropriate group to undergo the first round of vaccine testings. If the vaccine proves successful in ... has surveyed 644 homosexual men about their willingness to participate in a test of an AIDS vaccine. Forty-three percent said ...
The first preliminary human testing of a highly anticipated new kind of AIDS vaccine offers tantalizing hints it may ultimately ... The study of Merck & Co.s experimental vaccine is perhaps the most closely watched experiment in all of AIDS research. The ... It is a more traditional vaccine, made from the outer wrapper of the AIDS virus. Results are expected later this year. ... SEATTLE - The first preliminary human testing of a highly anticipated new kind of AIDS vaccine offers tantalizing hints it may ...
A POTENTIAL vaccine against HIV has produced encouraging results at a laboratory in Paris. Two chimpanzees, each of which ... smallpox vaccine - with an inserted gene from HIV. This gene makes the vaccinia. produce the protein from HIVs coat, called ... A POTENTIAL vaccine against HIV has produced encouraging results at. a laboratory in Paris. Two chimpanzees, each of which ... So even if scientists could design a vaccine that could stimulate. the body to produce one or more of these antibody types in ...
Eva Snead is the author of the book Some Call it Aids I Call it Murder in which she links Aids to vaccines. You can contact Eva ... I d say aids but my question would be, if that s a basis for aids how come only certain segments of the population would get it ... This is, they call it gland fever vaccine, they also call it flu vaccine and cold vaccine improperly called because adena virus ... Well the result was something that they called the polio vaccine and within a few years of the polio vaccine we started seeing ...
However, the vaccine did seem to lower the infection rate significantly among African-Americans and other non-Hispanic ... They conceded that the findings, though statistically significant, might change if the vaccine were tested among more members ... The first AIDS vaccine ever to be tested in a large number of people has failed, overall, to protect them from infection with ... totally unexpected and said they were at a loss to explain why there would be ethnic differences in response to the vaccine. ...
The long thwarted dream of an AIDS vaccine has been given a major shot in the arm with a new study that has rekindled hope ... Breakthrough raises hope for AIDS vaccine. By Joseph HallToronto Star. Thu., Sept. 3, 2009timer5. min. read ... The long thwarted dream of an AIDS vaccine has been given a major shot in the arm with a new study that has rekindled hope ... MacDonald, who has been front and centre in the global search for AIDS vaccines, did not contribute to the paper. But she says ...
AIDS Vaccine: Mixed Result, Possible Future. Despite questions, AIDS vaccine trial in Thailand spreads optimism ... Finding a vaccine has become an increasingly urgent undertaking. Despite advances in therapies, HIV/AIDS is still incurable. ... But rather than dashing all hopes for an AIDS vaccine, the trial has heartened some researchers, who see new clues in the ... "This contributes more evidence that an AIDS vaccine may be possible," says Jerome Kim of the Walter Reed Army Institute of ...
Now its also playing a leading role in the global quest for a way to prevent or even cure AIDS ... Now its also playing a leading role in the global quest for a way to prevent or even cure AIDS ... With the highest number of AIDS cases in the nation, New York City has long held center stage in infections. ... With the highest number of AIDS cases in the nation, New York City has long held center stage in infections. ...
... which considers that the need to stem the worldwide AIDS epidemic is greater than … ... Trials to test whether potential AIDS vaccines can prevent the disease should begin as soon as possible, without waiting to ... Wayne Koff, head of vaccines research at the NIH, outlined the policy. to a meeting of AIDS researchers in Paris last week. We ... Trials to test whether potential AIDS vaccines can prevent the disease. should begin as soon as possible, without waiting to ...
DNA vaccines have evolved as a clinically safe and effective platform for priming HIV-specific cellular and humoral responses ... Vaccines. 2014; 2(1):160-178. Chicago/Turabian Style. Iyer, Smita S.; Amara, Rama R. 2014. "DNA/MVA Vaccines for HIV/AIDS." ... Vaccines 2014, 2, 160-178. AMA Style. Iyer SS, Amara RR. DNA/MVA Vaccines for HIV/AIDS. ... DNA/MVA Vaccines for HIV/AIDS. Smita S. Iyer * and Rama R. Amara * ...
Ten Years Later, AIDS Vaccine Search Continues. Science gets closer, but a fully effective vaccine remains elusive ... a fully effective AIDS vaccine is a long way off. "There are people who will tell you we will never have a vaccine-I cant say ... But with the strides of recent years, it is no longer a question of whether we can develop an AIDS vaccine, it is simply a ... Ten years ago today, President Bill Clinton announced a national goal to develop an AIDS vaccine within a decade. At that time ...
... hygiene products and the COVID-19 vaccine. The Red Dirt Collective will host the event in partnership with other local ... May 20-Multiple Norman community groups will host a Mutual Aid Fair Saturday in the parking lot of Irving Middle School, where ... Mutual Aid Fair providing free groceries, vaccines in Norman. Read full article. ... May 20-Multiple Norman community groups will host a Mutual Aid Fair Saturday in the parking lot of Irving Middle School, where ...
... the virus that causes AIDS. That news is having an impact in the country hardest hit by AIDS - South Africa. ... Merck announced data showing that its experimental AIDS vaccine may have made people more susceptible to HIV, ... S. Africa Troubled by Problems with AIDS Vaccine Earlier this week, Merck announced data showing that its experimental AIDS ... After years of research, one of the most promising AIDS vaccines on the horizon was judged a failure. And it not only failed, ...
Huge AIDS Vaccine Trial Should Be Scrapped. By Philip Cohen. NewScientist.com 1-27-2. Two government agencies in the US are ... But one government AIDS researcher, who didnt want to be identified, was angered by Moores charges. The two trials cannot be ... If this was a vaccine that held real promise, the situation would be different, he says. But it doesnt merit such a huge ... In it, John Moore, an AIDS researcher at Cornell Universitys Weill Medical College in New York City, argues that one of the ...
... FOXNews.com ^ , Friday, March 21, 2008 , FOXNews.com Posted on 03/21/2008 5:39:05 ... KEYWORDS: aids; hiv; homosexualagenda; vaccine Navigation: use the links below to view more comments.. first previous 1-20, 21- ... There are vaccines against many of them (smallpox etc.), but the development of one for AIDS just hit the wall. I am not a ... The two-decade search for an AIDS vaccine is in crisis after two field tests of the most promising contender not only did not ...
2019 for the 17th annual AIDS Vaccine 200 bike ride benefitting Emory Universitys HIV/AIDS vaccine research. ...
... and researchers working to find a safe and effective vaccine to prevent HIV. Such a vaccine, along with existing HIV treatment ... and researchers working to find a safe and effective vaccine to prevent #HIV. Such a vaccine, along w/ existing HIV treatment ... and researchers working to find a safe and effective vaccine to prevent HIV. Such a vaccine, along with existing HIV treatment ... Led by the National Institute of Allergy and Infectious Diseasesexternal icon, HIV Vaccine Awareness Day (HVAD) is observed on ...
In addition, the rate of AIDS for HB vaccine recipients in CDC vaccine trials among homosexually active men in Denver and San ... In addition, epidemiologic monitoring of AIDS cases and high-risk groups confirms the lack of AIDS transmission by HB vaccine. ... Epidemiologic approaches to detect an association between HB vaccine and AIDS have included analysis of data on AIDS cases ... AIDS. The effect of the HB vaccine inactivation process on the AIDS virus and two other human retroviruses (HTLV-I and HTLV-II ...
Recombinant vectored vaccines. Recombinant vectored vaccines are most often used for vaccines that attempt to stimulate ... Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415: 335-339, 2002 ... Candidate HIV-1 tat vaccine development: from basic science to clinical trials. AIDS 20(18):2245-2261, 2006 ... The vaccine used in the STEP trial was an adenovirus vector, and one component of the vaccine used in the RV144 trial was ALVAC ...
The AIDS Healthcare Foundation distributed vaccines for bacterial meningitis on April 15, 2013 in response to the death of a ... AIDS Healthcare Foundation Gives Out Free Meningitis Vaccines. The AIDS Healthcare Foundation distributed vaccines for ... Published Monday, Apr 15, 2013) The AIDS Healthcare Foundation distributed vaccines for bacterial meningitis on April 15, 2013 ...
VIAV is linked to the AIDS Vaccine Integrated Project (AVIP),recently awarded by the EU Commission, for future product ... The aim of VIAV is to develop a highly innovative Env-based vaccine capable of inducing cross-clade neutralizing antibodies to ... for in vitro and in vivo s tudies 3.Evaluation of the safety and immunogenicity of different Tat/Env complex-based vaccine ... prevent HIV infection.This represents the most important problem of current Env-based vaccines.VIAV aim will be achieved ...
AIDS vaccine may be functional cure for some. By Jon Cohen. Feb. 22, 2017 , 4:45 PM. ... But when a field suffers as much failure as the search for an AIDS vaccine has over the past 30 years, researchers sometimes ... Mothe and her colleagues tried that strategy with an HIV vaccine made by Tomáš Hanke of the University of Oxford in the United ... Of more than 50 therapeutic vaccine trials so far, this is the first one that has bolstered the immune system in a "meaningful ...
Apply for International AIDS Vaccine Initiative jobs, learn about the culture, read reviews and more. Find International AIDS ... Want to work at International AIDS Vaccine Initiative? ... Vaccine Initiative careers in your area today! ...
But access to the vaccine is an issue of policy not science. One AIDS vaccine candidate is in final phase (phase III) trials, ... Dr Tim Tucker, head of South Africas Vaccine Initiative (SAVI), described ensuring access to the AIDS vaccine as the greatest ... developing an AIDS vaccine, the world is not ready to make and distribute such a vaccine should it become available soon, ... For An AIDS Vaccine. By Kerry Cullinan. Health-e.org. 6-10-2. Despite scientists optimism about the possibility of ...
Detailed results of the now-famous Thai AIDS vaccine trial confirmed that the vaccine is modestly effective, but hinted that ... HIV/AIDS > HIV/AIDS AIDS Vaccine Details Confirm Modest Benefit. Detailed results of the now-famous Thai AIDS vaccine trial ... Detailed results of the now-famous Thai AIDS vaccine trial confirmed that the vaccine is modestly effective, but hinted that ... Michael and colleagues presented details of the study at the AIDS Vaccine 2009 conference in Paris, and a formal peer-reviewed ...
International AIDS Vaccine Initiative receives 89.96 out of 100 for their Charity Navigator rating. International AIDS Vaccine ... International AIDS Vaccine Initiative is rated 3 out of 4 stars by Charity Navigator. ... International AIDS Vaccine Initiative Imagine a world without AIDS. ... I want to donate to International AIDS Vaccine Initiative Designate this donation to: ...
  • Wayne Koff, vice president of research at the International AIDS Vaccine Initiative and study co-author, says the paper could herald a 'renaissance' in the maligned and much thwarted field of HIV inoculation. (thestar.com)
  • The most important, the International AIDS Vaccine Initiative, is a 10-year-old private-public partnership. (crainsnewyork.com)
  • We have learned in that period of time how formidable an adversary HIV is," says immunologist Wayne Koff, senior vice president for research and development at the International AIDS Vaccine Initiative (IAVI). (scientificamerican.com)
  • Despite scientists' optimism about the possibility of developing an AIDS vaccine, the world is 'not ready' to make and distribute such a vaccine should it become available soon, according to Seth Berkley, president of the International AIDS Vaccine Initiative (IAVI). (rense.com)
  • The International AIDS Vaccine Initiative (IAVI) is a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges including HIV and tuberculosis. (charitynavigator.org)
  • All data for Financial Performance Metrics calculations was provided by International AIDS Vaccine Initiative on recent 990s filed with the IRS. (charitynavigator.org)
  • But the International AIDS Vaccine Initiative (IAVI) estimates less than 1% of the $70 billion spent yearly on global health product research is dedicated to AIDS vaccine research. (aljazeera.com)
  • Key Correspondents] The International AIDS Vaccine Initiative (IAVI) has published a report highlighting several milestones in the journey towards an AIDS vaccine. (medworm.com)
  • Dutch biotechnology company Crucell on Tuesday announced an exclusive licensing agreement with the International AIDS Vaccine Initiative to develop an AIDS vaccine based on the company's AdVac technology, Reuters reports. (thebody.com)
  • This research was funded by several grants from the National Institutes of Health, funding from the International AIDS Vaccine Initiative and a CAVD grant from the Bill & Melinda Gates Foundation. (innovations-report.com)
  • In regards to this research project, OHSU has licensed a CMV technology, of which Picker is an inventor, to the International AIDS Vaccine Initiative. (innovations-report.com)
  • Funders include The Bill and Melinda Gates Foundation, the Ford Foundation, the International AIDS Vaccine Initiative, Until There's a Cure Foundation, Broadway Cares/Equity Fights AIDS, the Gill Foundation, and the Overbrook Foundation. (wikipedia.org)
  • Paris (AFP) - The near 40-year quest for an AIDS vaccine received a hopeful boost Saturday when scientists announced that a trial drug triggered an immune response in humans and shielded monkeys from infection. (yahoo.com)
  • Shown to be safe in humans, the candidate vaccine has now advanced to the next phase of the pre-approval trial process, and will be tested in 2,600 women in southern Africa to see whether it prevents HIV infection. (yahoo.com)
  • study before we know whether or not this vaccine will protect humans against HIV infection," he said. (yahoo.com)
  • In a separate study, the same vaccine offered complete protection from infection in two-thirds of 72 trial monkeys each given six injections with an HIV-like virus. (yahoo.com)
  • HIV infection and AIDS death rates will continue to mount worldwide. (nih.gov)
  • However, even if the vaccine works, many experts doubt it will stop infection cold the way most vaccines do. (foxnews.com)
  • In monkey experiments, this strategy fails to ward off infection but does keep the animals from dying from AIDS when they are exposed to the virus. (foxnews.com)
  • The new vaccines are designed to launch a quick counterattack by blood cells called killer cells against a new HIV infection. (foxnews.com)
  • So even if scientists could design a vaccine that could stimulate the body to produce one or more of these antibody types in people, they might not protect completely against infection. (newscientist.com)
  • The first AIDS vaccine ever to be tested in a large number of people has failed, overall, to protect them from infection with the virus that causes the disease, the company that makes it, VaxGen, said on Sunday. (sun-sentinel.com)
  • However, the vaccine did seem to lower the infection rate significantly among African-Americans and other non-Hispanic minorities participating in the trial, the company said. (sun-sentinel.com)
  • Koff believes it is unrealistic to expect any vaccine to prevent the initial infection with HIV instead, researchers should aim at a vaccine that prevent HIV from becoming established in the body. (newscientist.com)
  • The past year has seen several animal experiments that provide solid evidence that vaccines can protect against infection with simian immune deficiency viruses (see This Week, 30 June). (newscientist.com)
  • Experts say that such a vaccine is unlikely to prevent the HIV infection. (scientificamerican.com)
  • We were instructed to, you know, permanently abort study, seize all immunizations and let the participants know that if they're wearing the vaccine on, there was a possibility that there was increased susceptibility to HIV infection. (npr.org)
  • and (3) look for serologic markers of infection from the AIDS virus in vaccine recipients. (cdc.gov)
  • Typically, vaccines are administered to large numbers of people at high risk of infection. (aidsmap.com)
  • Despite intensive efforts and massive investments, no vaccine to prevent HIV infection has yet proved itself and come to market. (sciencemag.org)
  • The vaccine reduced the risk of HIV infection by between 26% and 31.2%, depending on how the study population was analyzed, according to Nelson Michael, MD, PhD, of the Walter Reed Army Institute of Research in Rockville, Md. (medpagetoday.com)
  • The vaccine candidate in that study failed to protect against infection, and its failure cast a marked damper on the field. (medpagetoday.com)
  • But the company has not yet performed tests to see if the vaccine can protect chimpanzees from infection with the AIDS virus, and none of the other animals are subject to such infection. (nytimes.com)
  • The scientists will administer various doses of the vaccine to 60 healthy homosexual men who have no trace of the AIDS virus or AIDS antibodies in their blood and whose sexual behavior puts them at ''low risk'' of infection. (nytimes.com)
  • Just because it protected two-thirds of monkeys in a lab trial doesn't mean the drug will protect humans, "and thus we need to await the results of the… study before we know whether or not this vaccine will protect humans against HIV infection," he said. (rawstory.com)
  • World AIDS Vaccine Day serves as an opportunity to express gratitude towards scientists and researchers working in conjunction to find a safe an effective vaccine to prevent HIV infection. (ndtv.com)
  • There is currently no vaccine that will prevent HIV infection or treat those who have it. (ndtv.com)
  • Tat is produced extremely early upon virus entry, so this (vaccine) cripples the virus at the initial stage of the infection…So we don't speak about sterilising immunity. (aljazeera.com)
  • To minimize the chances of infection, it is important to know that cat AIDS is spread by saliva and blood. (vetinfo.com)
  • He hopes a vaccine will be developed so people can avoid infection in the future. (columbiachronicle.com)
  • Even a moderately effective vaccine would significantly decrease the burden of HIV disease over time in countries and populations with high rates of HIV infection, such as South Africa. (ibtimes.com)
  • Steven Self , a professor of biostatistics at the University of Washington, said the company should have lowered the level of confidence with which it said the vaccine appeared to protect blacks, Asians and other non-Hispanic minorities from infection by HIV. (sfgate.com)
  • But it said in a subset of 500 non-Hispanic minorities, the vaccine reduced infection by 66.8 percent, a statistically significant result. (sfgate.com)
  • New insights into how a subpopulation of helper T-cells provides immunity and promotes survival following infection with an AIDS-like virus offer a new means of predicting an AIDS vaccine's effectiveness, a discovery that could help scientists as they test these vaccines in clinical trials. (emaxhealth.com)
  • While this vaccine approach cannot actually prevent an infection, it can tamp down the AIDS virus, resulting in the development of a much milder form of the disease in vaccinated monkeys that subsequently become infected," he adds. (emaxhealth.com)
  • Until now, the success or failure of this type of T-cell vaccine has been determined by measures of virus levels and total counts of CD4+ helper T-cells, which are indicative of infection control in monkeys infected with the AIDS virus. (emaxhealth.com)
  • As in previous studies, this new research found that among monkeys infected with the simian immunodeficiency virus (SIV) -- 24 of which were vaccinated and six of which were not -- the immunity generated by the vaccine controlled infection for approximately 100 days before levels of virus increased and T-cell counts dropped. (emaxhealth.com)
  • This suggests that the initial protection that the vaccine provides in the early weeks following infection gives the monkeys a long-term survival advantage, and that this protection is associated with a significantly higher level of memory CD4+ cells. (emaxhealth.com)
  • The US government is poised to start a new AIDS vaccine trial, prompting some to caution that it is too soon to initiate such studies after a linkurl:Merck vaccine;https://www.the-scientist.com/blog/display/53633/ not only failed to show effectiveness but also may have increased participants' HIV infection rate. (the-scientist.com)
  • The GM-CSF-adjuvanted vaccine was added to GeoVax's portfolio because of the outstanding ability of the simian prototype vaccine to induce immune responses that prevented simian immunodeficiency virus (SIV) infection. (medicalnewstoday.com)
  • His discovery has led to characterization of the natural history of HPV infection, an understanding of mechanisms of HPV-induced carcinogenesis and the development of prophylactic vaccines against HPV acquisition,' the Assembly said. (dailymail.co.uk)
  • Such improved tests could identify people earlier in the course of their HIV infection or could more accurately assess the response to a vaccine. (poz.com)
  • HIV is an infection, and vaccines protect against disease, not infections. (clickondetroit.com)
  • With people being exposed to risk factors for HIV daily, there's more chance for infection that a vaccine doesn't prevent. (clickondetroit.com)
  • In the study of AIDS, it is important to understand the impact of viral infection, namely the loss of CD4+ helper T cells which is an indicator of the onset of AIDS. (originlab.com)
  • Last September, researchers reported their biggest success yet with a vaccine that appeared to slow the rate of infection by about 30 percent in Thai volunteers, but the trial raised many questions. (lifescript.com)
  • In this new study, they found that the vaccine produced 2 types of immune responses: One led to an increased vaccine efficacy, which means the vaccine would prevent infection. (cnn.com)
  • The other immune response led to the same infection rate as a placebo, according to Dr. Barton Haynes, Director of the Duke Human Vaccine Institute at Duke University School of Medicine. (cnn.com)
  • While a new DNA vaccine may not be able to prevent HIV infection, it could protect against progres sion to full-blown AIDS. (bio-medicine.org)
  • The scientists, reporting in today's New England Journal of Medicine, said that 19 of 30 volunteers who received injections of the vaccine showed an increase in antibodies and white blood cells that are components of the body's arsenal against infection. (baltimoresun.com)
  • Q: Why do you think that a vaccine is possible when the human immune system is unable to control an HIV infection? (baltimoresun.com)
  • The search for a safe and effective method to prevent HIV infection and AIDS is a long journey in which we should expect both success and failure," the authors write, before highlighting the lessons learned from the recent microbicide gel study and AIDS vaccine trial in Thailand . (kff.org)
  • A vaccine works by mimicking a natural infection. (moneycontrol.com)
  • A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. (moneycontrol.com)
  • To date, HIV infection has only been cured in a very small number of highly-publicized but unusual clinical cases in which HIV-infected individuals were treated with anti-viral medicines very early after the onset of infection or received a stem cell transplant to combat cancer," said Louis Picker, M.D., associate director of the OHSU Vaccine and Gene Therapy Institute. (innovations-report.com)
  • The Emory consortium will work to enhance the quality of antibody responses to HIV infection, building on recent Emory discoveries led by Amara and consortium member Bali Pulendran, PhD, using adjuvants to successfully enhance the effectiveness of vaccines against SIV infection. (rxpgnews.com)
  • The researchers will study how to develop a vaccine that can prevent the earliest stages of mucosal infection from simian immunodeficiency virus (SIV) in nonhuman primate models. (rxpgnews.com)
  • The series of research projects is expected to provide a better understanding of how SIV is transmitted sexually and the specific immune responses HIV vaccines must generate in humans to block infection at mucosal sites, prevent the establishment of systemic infection, or dramatically reduce the pathogenic effects of infection. (rxpgnews.com)
  • The results gave the vaccine research community hope that a vaccine could elicit antibodies that could at least moderately protect against HIV infection. (rxpgnews.com)
  • In order to develop an effective vaccine, scientists must understand the viral-host interaction during the initial time of mucosal infection. (rxpgnews.com)
  • By the time HIV-infected individuals begin experiencing the symptoms of acute HIV infection, this critical time of opportunity has passed, says Rama Amara, PhD, co-principal investigator of the consortium and a researcher at the Emory Vaccine Center and Yerkes Research Center. (rxpgnews.com)
  • Important follow-up questions the team will address include what kind of antigens and delivery system are needed to elicit protective antibodies, where should vaccines be delivered in the body, and how do adjuvants convert a poorly protective vaccine into one that fully protects against infection by the virus? (rxpgnews.com)
  • It describes the challenges facing vaccine researchers and the Institute's response, including basic and clinical research initiatives and advance planning for efficacy trials of the most promising candidate vaccines. (nih.gov)
  • To determine the feasibility of and develop the infrastructure for conducting such trials abroad, NIAID has awarded eight Preparation for AIDS/HIV Vaccine Evaluations (PAVE) grants to U.S. researchers and their international collaborators. (nih.gov)
  • Researchers attacked a monkey with AIDS virus after injecting the compound vaccine into its body, and found no abnormal reactions occurred. (chinadaily.com.cn)
  • Even though researchers have managed to infect a chimpanzee (I will leave aside here the many questions that arise concerning the morality of infecting a highly intelligent animal like a chimp with a lethal virus), the vaccine may function differently inside a chimp's body from the way it works inside a human being. (latimes.com)
  • Even though the vaccine is only part-way through first-stage safety testing, Merck's Emilio Emini was asked to update researchers in an address Tuesday at the 9th Annual Retrovirus Conference in Seattle. (foxnews.com)
  • The Merck researchers plan to try the vaccine on about 600 volunteers in the first-stage tests. (foxnews.com)
  • Its researchers called this finding totally unexpected and said they were at a loss to explain why there would be ethnic differences in response to the vaccine. (sun-sentinel.com)
  • But rather than dashing all hopes for an AIDS vaccine, the trial has heartened some researchers, who see new clues in the battle against the fatal illness. (scientificamerican.com)
  • That vaccine test, halted in 2007, got only as far as phase II, but even so it did not leave researchers back at square one. (scientificamerican.com)
  • To fend off HIV, researchers introduced one vaccine (ALVAC) to induce a T cell response-thereby alerting the immune system-and another (AIDSVAX) later to spur an antibody response. (scientificamerican.com)
  • Burton, along with 21 other researchers, co-authored a 2004 paper in Science criticizing the choice to proceed to phase III with two vaccines that had never demonstrated any effectiveness alone. (scientificamerican.com)
  • Wayne Koff, head of vaccines research at the NIH, outlined the policy to a meeting of AIDS researchers in Paris last week. (newscientist.com)
  • And if only 0.2 per cent of a population were infected, researchers might need to try the vaccine on as many as 40,000 volunteers. (newscientist.com)
  • The next two years will reveal whether researchers are on the right track for at least a partially effective vaccine. (scientificamerican.com)
  • In the early 1980s, after identifying the HIV virus as the cause of AIDS, researchers were confident they could come up with a vaccine against it within a few years, says Koff. (scientificamerican.com)
  • Early tests of a gp120 vaccine looked promising, but optimism faded by the early 1990s as researchers learned the vaccine only worked against strains of HIV that had adapted to conditions in the laboratory. (scientificamerican.com)
  • And it not only failed, data presented at a meeting of AIDS researchers in Seattle showed the vaccine may have increased the risk of HIV. (npr.org)
  • But Dennis Burton, an AIDS researcher at the Scripps Research Institute in California, says many researchers agree with Moore. (rense.com)
  • Today is HIV Vaccine Awareness Day, a day to recognize the volunteers, community members, and researchers working to find a safe and effective vaccine to prevent HIV. (cdc.gov)
  • But when a field suffers as much failure as the search for an AIDS vaccine has over the past 30 years, researchers sometimes celebrate glimpses of hope. (sciencemag.org)
  • Researchers have also tested so-called therapeutic vaccines, which aim to help infected people keep the virus at bay for months or even years without antiretroviral (ARV) drugs. (sciencemag.org)
  • But the researchers added two other efficacy analyses that did not reach statistical significance, but which, they said, bolster their view that the vaccine had a protective effect. (medpagetoday.com)
  • Other companies are also working on potential vaccines, as are scores if not hundreds of researchers at institutions around the world. (nytimes.com)
  • In session after session, AIDS researchers reported results from novel vaccine experiments that have worked to various degrees in monkeys. (sciencemag.org)
  • Pharmaceutical researchers are continuing their efforts to develop new therapies and vaccines to improve and lengthen the lives of HIV-infected patients. (medindia.net)
  • Spanish researchers announced they have developed an Aids vaccine which cuts the viral load by a significant amount in most patients. (health24.com)
  • This news makes Bob, 47, an HIV-positive photographer from New York City, hopeful that a vaccine is around the corner, although he thinks researchers have a long way to go before that goal is reached. (columbiachronicle.com)
  • The United States National Institutes of Health (NIH) has awarded the four researchers $2.7 million to help them improve the effectiveness of a DNA-based vaccine that Marinieve Montero first conceived of eight years ago. (sfu.ca)
  • The researchers will use their new funding to strengthen a vaccine they've made from a DNA fragment taken from the HIV genome. (sfu.ca)
  • While other researchers have made vaccines that expose a subject's immune system to a synthetic version of the MPER, the vaccines have not triggered the production of antibodies that recognize and attack HIV. (sfu.ca)
  • During the next four years, the researchers will test their improved MPER vaccines, which they hope will induce antibodies that are aggressive enough to prevent HIV from infecting lab subjects. (sfu.ca)
  • Led by researchers at Beth Israel Deaconess Medical Center (BIDMC) and the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, the findings appear in the June 9 issue of the journal Science. (emaxhealth.com)
  • An HIV-positive woman who has never shown symptoms of the virus might provide insights into HIV/AIDS vaccine development, researchers from Johns Hopkins University said in a study recently published in the Journal of Virology, Reuters reports. (emaxhealth.com)
  • However, the cytokines cannot explain the woman's ability to suppress HIV , Reuters reports, because HIV/AIDS researchers have tried using such immune system proteins in patients and found they did not work well. (emaxhealth.com)
  • The novel strategy used in developing this vaccine enables researchers to circumvent preexisting immunity to the adenovirus serotype 5, the virus responsible for the common cold, which has recently shown limitations as an HIV-1 vaccine vector. (biologynews.net)
  • The Food and Drug Administration has given Canadian researchers approval to test a vaccine for HIV/AIDS on humans. (bio.org)
  • Researchers from the University of Western Ontario are hopeful that with further tests, a vaccine could be on the market in about five years. (bio.org)
  • June 10, 2018 - Atlanta, GA - Researchers from GeoVax have developed a flexible "Plug and Play" technology platform that delivers single-dose vaccines that fully protect against emerging infectious diseases such as Zika, Lassa fever, and Ebola. (eurekalert.org)
  • In proof-of-concept studies, the researchers tested three independent vaccines against three different families of viruses. (eurekalert.org)
  • A group of researchers including Nadeem Sheikh at the Washington National Primate Research Center are currently performing in depth research into various aspects of human biology, specializing in the development and assessment of AIDS vaccine efficacy. (originlab.com)
  • WASHINGTON (Reuters) - Researchers have discovered antibodies that can protect against a wide range of AIDS viruses and said they may be able to use them to design a vaccine against the fatal and incurable virus. (lifescript.com)
  • But a properly designed vaccine might help the body make them much sooner, the researchers reported in Friday's issue of the journal Science. (lifescript.com)
  • Researchers have been looking for parts of the virus that do not mutate so they can design vaccines that will protect against these constantly changing versions. (lifescript.com)
  • Being able to "see" what the structure looks like could enable researchers to design a vaccine using a process called rational vaccine design, akin to an established technique for making drugs called rational drug design, Nabel said. (lifescript.com)
  • One of the antibodies, called VRC01, partially mimics the way an immune cell called a CD4 T-cell attaches to a piece of the AIDS virus called gp120, the researchers said. (lifescript.com)
  • After 2 years of analyzing the results of the largest AIDS vaccine clinical trial ever held - called RV144 - researchers say they have found 2 ways the immune system can respond, which could predict whether those inoculated will be protected or are more likely to become infected with HIV. (cnn.com)
  • Since then researchers have culled data from the study looking for clues as to why the vaccine protected some but not others. (cnn.com)
  • But some researchers here say the vaccine is still the 'holy grail. (cnn.com)
  • But even with this modest advance researchers say, there's still a lot to be done before a vaccine is ready globally and for the general public. (cnn.com)
  • Developing a vaccine to protect against HIV in attempt to gain control of the AIDS pandemic is a top priority for researchers throughout the world. (bio-medicine.org)
  • The results showed strong evidence that this type of vaccine could prevent AIDS and established that a DNA vaccine, such as this one, could be used alone, without the need for booster doses with viral proteins, for large-scale immunization programs," say the researchers. (bio-medicine.org)
  • Army researchers say an experimental AIDS vaccine has triggered an immune response in patients who already carried the virus -- a hopeful sign that a vaccine may someday be LTC capable of prolonging lives. (baltimoresun.com)
  • But the researchers expressed caution, too, explaining that the trial at the Walter Reed Army Medical Center has not yet demonstrated that the vaccine is capable of halting the spread of the AIDS virus -- orthat vaccinated patients will live any longer than people who receive no vaccine. (baltimoresun.com)
  • but it all seems to make excellent business sense, if you are a drug company shareholder or one of the thousands of researchers who work "to find a cure" for AIDS. (newmediaexplorer.org)
  • An HIV/AIDS vaccine candidate developed by researchers at Oregon Health & Science University appears to have the ability to completely clear an AIDS-causing virus from the body. (innovations-report.com)
  • Researchers agree that a successful HIV vaccine will likely need to elicit both effective T-cell and antibody responses. (rxpgnews.com)
  • RxPG] A consortium of leading vaccine researchers at Emory University and partner institutions has received a National Institutes of Health (NIH) grant aimed at developing an effective HIV/AIDS vaccine. (rxpgnews.com)
  • With the vast experience of Emory's vaccine researchers and our partners, I'm confident we can make significant strides in developing a better HIV vaccine. (rxpgnews.com)
  • In order to develop a more effective vaccine, however, researchers need to further explore the specific aspects of the immune response (referred to as correlates of immunity) in animal models as well as in human clinical trials, Hunter explains. (rxpgnews.com)
  • However, more than a third of those surveyed, 273 men in all, responded that they are willing both to be tested and to volunteer if they are determined not to be carrying antibodies to the AIDS virus. (latimes.com)
  • The search for a vaccine against HIV has so far eluded scientists, partly because the virus mutates rapidly and - unlike other human viruses - comes in many different forms that make the body produce many different types of antibodies. (newscientist.com)
  • First, it had a classical 'vaccine' of inactivated virus, which produced only very few neutralising antibodies. (newscientist.com)
  • But the pair of previously unknown antibodies revealed in the paper - discovered in the blood of an unidentified African AIDS patient and known as PG9 and PG16 - appear to neutralize HIV's ability to infect its immune cell targets in almost 80 per cent of cases. (thestar.com)
  • In addition, safety trials at Johns Hopkins University and elsewhere in the US have shown that several potential vaccines are safe in healthy volunteers and that they stimulate antibodies and cells of the immune system. (newscientist.com)
  • Vaccines work by exposing the body to the disease-causing agent or a fragment of it, which primes the immune system to produce a flood of antibodies that stick to the infecting organism and block it from entering cells. (scientificamerican.com)
  • The third approach attempted to detect seroconversion to AIDS virus antibodies in paired sera of HB vaccine recipients. (cdc.gov)
  • As described in What an HIV vaccine would have to do , this may involve assessing the antibodies present in their blood, or the response of their CD8 T-cells to HIV in the test tube, or looking for HIV seroconversions in the trial participants. (aidsmap.com)
  • Examples include a vector virus to prime a T-cell response with a subunit (peptide) booster or DNA vaccine to produce antibodies, or two different vector viruses expressing the same gene sequence. (aidsmap.com)
  • HIV surface proteins (salmon) rapidly mutate to dodge antibodies (lime and blue) so some vaccines direct immune responses to viral pieces that rarely change. (sciencemag.org)
  • The study will investigate only the safety of the vaccine and the degree to which it stimulates protective antibodies in the recipients. (nytimes.com)
  • Officials said the MicroGeneSys vaccine was the first to gain approval for human testing in part because the company completed the preliminary requirements first, and in part because its vaccine looked highly promising in stimulating the production of neutralizing antibodies in animal tests. (nytimes.com)
  • Such antibodies are the part of the immune system that is expected to fight off the AIDS virus. (nytimes.com)
  • Vaccines work through the injection of viral proteins into the body to stimulate the immune system to produce antibodies that protect cells from invading viruses like H.I.V., which causes AIDS. (nytimes.com)
  • Patients whose blood contained high levels of a different antibody called IgA appeared to have less protection against HIV than their IgG-loaded counterparts, leading scientists to believe that these antibodies could play a critical role in developing an effective vaccine. (columbiachronicle.com)
  • Attempts to develop an HIV vaccine that triggers the production of antibodies -- the mechanism responsible for vaccine protection against other viruses including polio and hepatitis B -- have been unsuccessful. (emaxhealth.com)
  • http://www.macrovolt.com/live/dgi_053008/default.aspx According to the NIAID, the vaccine will be tested in the US on 2,400 men who have sex with other men, but trial participants must not have detectable Ad5 antibodies and must be circumcised - the two main differences in enrollment criteria from the failed Merck trial. (the-scientist.com)
  • The GM-CSF-adjuvanted vaccine induced the production of antibodies characterized with increased tightness of antibody binding. (medicalnewstoday.com)
  • Because it can measure much smaller amounts of the antibodies, the test may help more accurately determine the efficacy of vaccines. (poz.com)
  • This is a product-specific license agreement that does not preclude Immunomedics from continuing to develop or to license DNL for vaccines or other applications such as multispecific monoclonal antibodies, PEG- or IgG-linked proteins, targeted siRNA or drug constructs, but does enable us to apply our DNL technology to the innovative peptide-based vaccines being developed by Alexis Biotech," commented Cynthia L. Sullivan, President and CEO of Immunomedics, Inc. (fiercebiotech.com)
  • Two of the antibodies can attach to and neutralize 90 percent of the various mutations of the human immunodeficiency virus that causes AIDS, Nabel said. (lifescript.com)
  • The discovery of these exceptionally broadly neutralizing antibodies to HIV and the structural analysis that explains how they work are exciting advances that will accelerate our efforts to find a preventive HIV vaccine for global use," NIAID director Dr. Anthony Fauci added in a statement. (lifescript.com)
  • In addition, the technique the teams used to find the new antibodies represents a novel strategy that could be applied to vaccine design for many other infectious diseases. (lifescript.com)
  • Most vaccines depend on the induction of antibodies in our bodies to be effective, but HIV has hidden away its crown jewels, making them largely inaccessible to antibodies. (baltimoresun.com)
  • One vaccine now in human testing is based on induction of antibodies, but it is given very little hope of success. (baltimoresun.com)
  • GM-CSF is a normal protein that promotes the initiation of immune responses and thus enhances the ability of the vaccine to elicit blocking antibodies for the SIV virus before it enters cells. (scienceblog.com)
  • Teams of scientists from industry, academia and government collaborate to develop and test novel experimental HIV vaccine concepts in the laboratory and in animal models. (nih.gov)
  • Since virtually everyone has been exposed to ordinary varieties of this microbe, known as an adenovirus, the scientists worry the vaccine will be destroyed immediately by the immune system. (foxnews.com)
  • Scientists say they may know within months how fast and well this new HIV target can be employed in a vaccine strategy. (thestar.com)
  • This event is an opportunity to recognize the many volunteers, community members, health professionals, and scientists who are working together to find a safe and effective vaccine to prevent HIV. (cdc.gov)
  • That's what happened here last week when scientists showed that a vaccine may have helped five people already infected with HIV keep the virus in check-a "functional cure" as some call it. (sciencemag.org)
  • After Tuesday's review of the modest positive results of the recent Thailand AIDS vaccine trials, scientists heard about research to improve the chance of finding a much more effective vaccine. (voanews.com)
  • Ending AIDS: The Search for a Vaccine asks why an AIDS vaccine has been so elusive, what progress we are making, and what obstacles continue to stump some of the most brilliant scientists in the world. (macfound.org)
  • The day gives us an opportunity to say a big 'thank you' to the scientists, healthworkers, community members and social workers who are tirelessly trying to raise awareness about HIV and AIDS. (ndtv.com)
  • Scientists are however working to develop a vaccine for AIDS. (ndtv.com)
  • However, a new analysis of a 2009 AIDS vaccine trial has brought scientists one step closer to finding a preventive. (columbiachronicle.com)
  • They may also help scientists prioritize vaccine candidates for future clinical trials, which would accelerate the development of a vaccine. (columbiachronicle.com)
  • The company has since been criticized by outside scientists and AIDS activists for stressing conclusions based on a small number of patients. (sfgate.com)
  • Instead, Letvin and other scientists in this field have focused their work on developing a vaccine that confers cellular immunity, so that a group of T-cells induced by a vaccine recognizes the cells that have been infected by HIV and then destroys them so that the virus cannot continue replicating. (emaxhealth.com)
  • By measuring the levels of central memory cells in blood samples taken from participants in human clinical trials [to test the AIDS vaccine] scientists would be able to predict how well the vaccine would work over time. (emaxhealth.com)
  • The [vaccine] regimen is sufficiently different from the Merck product to warrant further testing," linkurl:Eric Hunter,;http://www.vaccines.emory.edu/scientists/hunter.shtml Emory University vaccinologist and subcommittee chair, said at the panel's linkurl:meeting. (the-scientist.com)
  • The HVTN plans to clinically test a novel vaccine product developed by GeoVax scientists that expresses human granulocyte-macrophage colony stimulating factor (GM-CSF) in combination with inactivated HIV proteins. (medicalnewstoday.com)
  • JUPITER, FL - September 23, 2015 - Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded up to nearly $6 million dollars from the Bill & Melinda Gates Foundation to develop a revolutionary HIV/AIDS alternative vaccine that has demonstrated great potential in animal models. (eurekalert.org)
  • The vaccine in question was developed by Hilary Koprowski and Stanley Plotkin, a pair of scientists from the Wistar Institute in Philadelphia, the country's first independent medical research center. (dynamicchiropractic.com)
  • The new data was released at the annual AIDS Vaccine conference, the largest scientific venue that brings together the world's top scientists, policy makers, community advocates and funders who focus exclusively on AIDS vaccine research. (cnn.com)
  • Several years of further testing will be needed before scientists will know whether the vaccine, called GP-160, is capable of accomplishing this, he said. (baltimoresun.com)
  • Many of the world's AIDS research scientists met last week in South Africa, a country that has one of the greatest rates of spread of the disease in the last few years. (baltimoresun.com)
  • While these scientists heard many papers and debated many issues, what they did not hear in Durban was exciting news about an AIDS vaccine -- the only way to stop the spread of AIDS. (baltimoresun.com)
  • Yet 5000 scientists signed a declaration that HIV is the sole cause of AIDS. (newmediaexplorer.org)
  • Scientists at Emory University and GeoVax Labs, Inc. developed a vaccine that has protected nonhuman primates against multiple exposures to simian immunodeficiency virus (SIV) given in three clusters over more than three years. (scienceblog.com)
  • Donald Trump praised the scientists working on developing a COVID-19 vaccine for their past remarkable achievement: the AIDS vaccine. (hollywoodlife.com)
  • While swearing to an audience at the White House that there would be a vaccine or cure for COVID-19 "by the end of the year," President Donald Trump took time to thank the "incredible doctors and scientists" who have developed other medical marvels - like the AIDS vaccine. (hollywoodlife.com)
  • By the early to mid- 1990s, the AIDS vaccine effort was relatively moribund," says IAVI president Seth Berkley, who founded the group in 1996. (scientificamerican.com)
  • According to an IAVI report released in July, more than 30 vaccines are currently in clinical trials. (thebody.com)
  • IAVI has called for $1.3 billion in funding for vaccine development. (thebody.com)
  • IAVI President and CEO Seth Berkley said that annual spending on vaccine research is about $650 million -- less than 1% of the total spending on all HIV/AIDS product development ( Kaiser Daily HIV/AIDS Report , 7/13). (thebody.com)
  • Master Contracts for Preclinical HIV Vaccine Development provide flexible resources for the preclinical development of the most promising HIV vaccine candidates. (nih.gov)
  • These resources include vaccine production, preclinical evaluation of vaccines in nonhuman primates and the development of biological and chemical substances called reagents for use in comparative vaccine studies. (nih.gov)
  • Here, we review preclinical studies on the DNA-prime/modified vaccinia Ankara (MVA)-boost vaccine modality for HIV. (mdpi.com)
  • That recognition, he says, led to greater resources being put into basic and preclinical science, or upstream science, "that wasn't around vaccine candidates per se at the time, but again focusing on some of these big scientific questions about how the virus worked, about the structure of the virus. (voanews.com)
  • This funding initiative addresses two objectives of the FY 2016 National Institutes of Health Trans-NIH Plan for HIV-Related Research: 1) To explore new HIV vaccine approaches, and 2) To develop opportunities for new investigators in the HIV vaccine field, enabling them to translate promising preclinical vaccine studies in NHPs into human clinical trials. (nih.gov)
  • The rAd26 vaccine vector was selected for its particularly low seroprevalence in human populations and for its potent immunogenicity and protective efficacy in preclinical studies," explains Dan H. Barouch, MD, PhD, Associate Professor of Medicine at Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical School and Principal Investigator of the Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) program that developed the vaccine. (biologynews.net)
  • On the next page, learn about the AIDS vaccine preclinical trials. (howstuffworks.com)
  • This is only the fifth HIV vaccine concept that will be tested for efficacy in humans in the 35+ year history of the global HIV epidemic," added Barouch. (yahoo.com)
  • Robinson projects that Phase III efficacy trials of the AIDS vaccine could begin in 2006. (emory.edu)
  • Explain to interested patients that this large study is the first to show that an HIV vaccine candidate can protect against the virus, although the benefit was modest and only reached statistical significance in one of three efficacy analyses. (medpagetoday.com)
  • On the other hand, a new analysis of when infections took place hints that the vaccine was most protective shortly after vaccination and then waned, but Michael said that decrease in efficacy did not reach statistical significance. (medpagetoday.com)
  • In November 2007, a large multinational trial called Step, evaluating the lead candidate in what the HIV vaccine field termed T cell-based vaccines, was halted at its first interim analyses because of the vaccine's lack of efficacy [1,2] . (lww.com)
  • The AIDS vaccine is currently being tested for its safety and efficacy on over 200 human volunteers in America and Uganda. (medindia.net)
  • That meant there was a 95 percent probability that the actual efficacy of the vaccine in the subgroup was between those points. (sfgate.com)
  • These latest findings now provide us with an important new way of looking at subpopulations of CD4 helper T-cells and suggest how they may be used as a marker to gauge the efficacy of these vaccines. (emaxhealth.com)
  • It also suggests that the measurement of this cell in the blood of vaccinated individuals who subsequently become infected with HIV may provide an important predictor of vaccine efficacy. (emaxhealth.com)
  • These trials, supported and conducted by the National Institutes of Health HIV Vaccine Trials Network, have set the stage for the second-generation GM-CSF co-expressing vaccine to move from its initial Phase 1 safety testing slated to start in March of this year to a Phase 2b efficacy trial in participants who are at high risk of exposure to HIV. (scienceblog.com)
  • Developing a safe and effective vaccine to curb the human and economic costs of the HIV/AIDS pandemic has become an international health priority. (nih.gov)
  • It will probably be at least a decade before a safe and effective vaccine is ready to market. (crainsnewyork.com)
  • If deployed alongside our current armory of proven HIV prevention tools, a safe and effective vaccine could be the final nail in the coffin for HIV," Anthony Fauci, director of the U.S. government's National Institute of Allergy and Infectious Diseases (NIAID), said in a statement Sunday. (ibtimes.com)
  • According to a Yerkes study reported in the October 2002 edition of the Journal of Virology, levels of viral DNA in the monkeys have declined to the nearly undetectable levels characteristic of a small subset of HIV-infected people, termed long-term nonprogressors, who carry HIV but do not develop AIDS. (emory.edu)
  • Like other viral diseases, including small pox and polio, AlDS may disappear from the scene with the development of a vaccine. (latimes.com)
  • The May 30 issue of Science reports that Viral Technologies Inc., a Washington corporation, has managed to prevent the AIDS virus from invading human cells inside a test tube. (latimes.com)
  • A vaccine mimics the viral region where the antigens sit, and train the immune system to recognize and attack the virus in that vital spot when the real thing enters the blood stream. (thestar.com)
  • The last two decades have seen significant progress in the DNA-based vaccine platform with optimized plasmid constructs, improved delivery methods, such as electroporation, the use of molecular adjuvants and novel strategies combining DNA with viral vectors and subunit proteins. (mdpi.com)
  • Drugmakers Merck and sanofi-aventis have each made versions of a T cell-stimulating vaccine by inserting HIV genes into a viral vector, or gene delivery system. (scientificamerican.com)
  • Vaccines against viral toxins. (aidsmap.com)
  • The vaccine candidate used in Step included a replication incompetent adenovirus type 5 (Ad5) viral vector, and the objectives of the trial were to investigate whether this candidate vaccine was able to reduce HIV acquisition or to modulate viral load [3] . (lww.com)
  • Thus, the lack of success of the vaccine, especially on controlling postinfection viral load (setpoint viremia) among vaccinated individuals who became infected, has sent reverberations throughout the scientific community for its implications on our ability to develop a globally effective HIV vaccine. (lww.com)
  • Scott and her partners believe this is because synthetic MPER vaccines to-date have not replicated the viral MPER accurately, but say their new vaccines do a better job. (sfu.ca)
  • Over the last decade, we have created AIDS vaccines that generate T-cell populations that can combat HIV," explains lead author Norman Letvin, M.D., chief of the Division of Viral Pathogenesis at BIDMC, professor of Medicine at Harvard Medical School, and investigator at the NIAID VRC. (emaxhealth.com)
  • First, Girard gave it genetically engineered vaccinia virus - the basis of traditional smallpox vaccine - with an inserted gene from HIV. (newscientist.com)
  • However, when the specimens of vaccine are investigated today that were made with the original virus, the peculiar thing is that the studies yield neither smallpox nor cowpox but a separate virus which has now been called vaccinia. (whale.to)
  • There are vaccines against many of them (smallpox etc.), but the development of one for AIDS just hit the wall. (freerepublic.com)
  • Vaccines against viruses can produce miracles -- smallpox was eradicated from the world with a vaccine and polio is almost eradicated. (baltimoresun.com)
  • Siga was trying to get a contract to sell the government 1.7 million doses of smallpox vaccine, but ran into some major problems. (westernjournalism.com)
  • It seems that the government already has a billion-dollar stockpile of a smallpox vaccine that is known to work. (westernjournalism.com)
  • In this case, the subject receives a genetically altered version of a weak smallpox vaccine called MVA . (howstuffworks.com)
  • It's the only sensible thing to do,' said Jonas Salk, the inventor of polio vaccine. (newscientist.com)
  • They (the states) said they wanted to conduct tests on the oral polio vaccine to be sure it does not contain HIV and family planning materials,' Chukwuani said. (scribd.com)
  • Dr Datti Ahmed, president of Nigeria's Supreme Council for Sharia Law, told Reuters: 'A lot of documents have come into our possession indicating there are grave doubts and concerns about the safety of the oral polio vaccine being used in Nigeria. (scribd.com)
  • Did a Polio Vaccine Cause AIDS? (dynamicchiropractic.com)
  • Evidence uncovered through interviews and literary searches suggests that the AIDS virus was not the byproduct of a communist plot or a form of divine punishment, but that it may be the result of a contaminated experimental polio vaccine program conducted in Africa in the late 1950s. (dynamicchiropractic.com)
  • At the time, the institute was one of several organizations competing to develop an effective attenuated polio vaccine that could be dispensed quickly to protect people from catching the disease. (dynamicchiropractic.com)
  • Kinshasa, the country's largest city, is considered one of the birthplaces of the AIDS epidemic, and was one of the first places the experimental polio vaccine was tested. (dynamicchiropractic.com)
  • Dr. Jonas Salk, pioneer of the polio vaccine, said last year that a vaccine made from whole, killed AIDS virus appeared to have kept many infected patients from progressing to the full-blown disease. (baltimoresun.com)
  • Emory's AIDS vaccine consists of two components: a DNA prime and a recombinant poxvirus as a booster. (emory.edu)
  • Recombinant sub-unit vaccines. (aidsmap.com)
  • Recombinant vectored vaccines. (aidsmap.com)
  • The new vaccine - like the failed Merck vaccine - uses a recombinant vaccine based on adenovirus type 5 (Ad5), but administers a single injection after a "prime-boost" of three DNA-based immunizations designed to stimulate the immune system. (the-scientist.com)
  • The novel vaccine consists of a recombinant DNA vaccine co-expressing human GM-CSF and non-infectious HIV viruslike particles. (medicalnewstoday.com)
  • The DNA vaccine is used to prime immune responses that are subsequently boosted by vaccination with a recombinant modified vaccinia Ankara (MVA) vectored vaccine. (medicalnewstoday.com)
  • The vaccine consists of a replication-incompetent, recombinant adenovirus serotype 26 (rAd26) vector encoding an HIV-1 envelope gene. (biologynews.net)
  • and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine. (moneycontrol.com)
  • The study of Merck & Co.'s experimental vaccine is perhaps the most closely watched experiment in all of AIDS research. (foxnews.com)
  • The difficulty of developing a vaccine has been one of the biggest frustrations in AIDS research, and experts were enthusiastic Tuesday about the Merck results. (foxnews.com)
  • The Merck vaccine and several similar ones nearing human testing use a strategy called prime-boost. (foxnews.com)
  • Vaccine proponents also point to the lessons learned from the failed Merck STEP trial. (scientificamerican.com)
  • Clinical trials of several promising vaccines--including Merck & Co.'s AD-5, which Mr. Bradley is helping test--are under way at many of Manhattan's major medical institutions, including New York-Presbyterian/Columbia University Medical Center, the New York Blood Center and Rockefeller University's Aaron Diamond Research Center, as well as NYU. (crainsnewyork.com)
  • Earlier this week, Merck announced data showing that its experimental AIDS vaccine may have made people more susceptible to HIV, the virus that causes AIDS. (npr.org)
  • BRENDA WILSON: In South Africa, the clinical trial of the Merck vaccine is called Phambili, which means moving forward. (npr.org)
  • In separate studies conducted between CDC and the vaccine manufacturer Merck, Sharp & Dohme (MSD), and between State University of New York (SUNY) Upstate Medical Center and MSD, cell culture supernatant fluid containing the AIDS virus and cultured cells containing HTLV-I, HTLV-II, and the AIDS virus were transported to MSD and individually exposed to the three inactivation steps. (cdc.gov)
  • But things have changed in recent years, due in part to the unsuccessful Merck vaccine trial and the modestly successful Thai vaccine trial. (voanews.com)
  • The failed Merck Ad5 vaccine was administered in three sequential injections, with no prior DNA-based priming. (the-scientist.com)
  • In light of recent setbacks, such as the disappointing closure of the Merck HIV vaccine trial, such findings suggest that we should not overlook potential "social vaccines" which, in addition to biomedical interventions, can play a critical role in HIV prevention. (innovations-report.com)
  • If this is successful, I feel like I might be part of history, like the people who volunteered for the hepatitis vaccine and saved so many others," he says. (crainsnewyork.com)
  • National Cooperative Vaccine Development Groups (NCVDGs) represent the core HIV vaccine discovery and development effort sponsored by NIAID. (nih.gov)
  • Most likely we will have to have a third trial to test the combined regimen of the DNA and booster portions of the vaccine," said Harriet Robinson, chief of the Yerkes Division of Microbiology and Immunology, who led the development of the vaccine. (emory.edu)
  • However, the insufficient magnitude of this response has led to the development of approaches for enhancing the immunogenicity of DNA vaccines. (mdpi.com)
  • Other delegates suggested tax incentives for businesses who invested in vaccine research, which is far more costly and less profitable than drug development. (rense.com)
  • In formally announcing the decision, which was disclosed in news reports Monday, Federal health officials expressed hope and optimism about the new vaccine but said there was nothing about its development that suggested an imminent breakthrough in preventing the deadly disease, which cripples the immune system. (nytimes.com)
  • And that's one way to slice and dice the vaccine development process. (voanews.com)
  • but rather vaccine discovery and vaccine development. (voanews.com)
  • The report stated that the 97 products in development include 23 vaccines and 54 antivirals. (medindia.net)
  • In his book and talk, Mr. Cohen describes some of the principal obstacles to the development of an effective AIDS vaccine. (c-span.org)
  • The stock of Sheffield Medical Technologies Inc., a medical development company based in Houston, rose yesterday on news that the company had acquired a worldwide license to an H.I.V.-AIDS vaccine technology under development. (nytimes.com)
  • Their findings could help inform the development of vaccines for these types of infections. (nextbillion.net)
  • Research and mentorship must be in the field of HIV/AIDS vaccine development, using nonhuman primates (NHPs) as pre-clinical models. (nih.gov)
  • These awards will provide 3 years of support for intensive research career development under the guidance of an experienced mentorship team, with expertise in both development of NHP vaccine models and in translation of the results of investigations performed in NHPs to work in humans. (nih.gov)
  • Now the company has decided to expand its preventative HIV/AIDS vaccine development effort in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH) and the HIV Vaccine Trials Network (HVTN). (medicalnewstoday.com)
  • AIDS and HIV, a virus that can lead to the development of AIDS, became a major global concern in the '80s and '90s, with the first known reports of the disease in the United States dating to 1981. (clickondetroit.com)
  • Manufactured by the Dutch biotechnology company Crucell Holland BV, the rAd26 vaccine is the first HIV-1 vaccine candidate to emerge from the IPCAVD initiative, which brings together investigators from academia and industry in an effort to accelerate the development of promising HIV/AIDS vaccine candidates. (biologynews.net)
  • Similar to the approaches used to develop vaccines for polio, influenza, rabies and hepatitis A, the vaccine is the first based on a genetically modified, killed whole virus and is the only HIV vaccine currently under development in Canada, and one of the only few in the world. (bio.org)
  • Nadeem Sheikh is an immunologist working on AIDS vaccine development at the Washington National Primate Research Center, University of Washington. (originlab.com)
  • NIAID seeks to establish a Center for HIV/AIDS Vaccine Immunology (CHAVI) that will support intensive and highly collaborative projects addressing key immunological roadblocks to the discovery and development of a safe and effective HIV vaccine as defined by NIAID and identified by the Global HIV Vaccine Enterprise. (nih.gov)
  • Vaccine development is a long, complex process. (moneycontrol.com)
  • The intellectual property for the vaccine has been exclusively licensed from Emory by GeoVax for clinical development. (scienceblog.com)
  • Following further development, it is hoped an HIV-form of the vaccine candidate can soon be tested in humans. (innovations-report.com)
  • AVAC is a New York City-based international non-profit community- and consumer-based organization working to accelerate ethical development and delivery of AIDS vaccines and other HIV prevention options to populations throughout the world. (wikipedia.org)
  • AVAC works to provide independent analysis, policy advocacy, public education and mobilisation to enhance AIDS vaccine research and development. (wikipedia.org)
  • That news is having an impact in the country hardest hit by AIDS - South Africa. (npr.org)
  • In South Africa, it could stir up a debate about the scientific consensus on HIV and AIDS that has repeatedly been challenged by the government. (npr.org)
  • Just before this year's World AIDS Day, South Africa launched a multiyear trial of a vaccine that might save millions of lives and help put an end to AIDS. (voanews.com)
  • I cannot emphasise how badly we need to have a vaccine… to get rid of HIV in the next generation altogether," said Francois Venter of the University of the Witwatersrand Reproductive Health and HIV Institute in South Africa. (rawstory.com)
  • A new clinical trial will be launched in South Africa Wednesday on an experimental vaccine that could prevent HIV, the virus that causes AIDS. (ibtimes.com)
  • According to a statement from the National Institutes of Health (NIH), HVTN 702 is the largest and most advanced HIV vaccine clinical trial to be undertaken in South Africa, where more than 1,000 people are infected with HIV in a day. (ibtimes.com)
  • If an HIV vaccine were found to work in South Africa, it could dramatically alter the course of the pandemic," Glenda Gray, president and CEO of the South African Medical Research Council, said, according to reports . (ibtimes.com)
  • In 2010, the CAPRISA 004 (Centre for the AIDS Programme of Research In South Africa) showed a 39% reduction in new HIV infections in sexually active, HIV-negative South African women using tenofovir gel, an antiretroviral (ARV) microbicide . (cnn.com)
  • Inevitably, promising candidate HIV vaccines suitable for testing of their effectiveness will be identified. (nih.gov)
  • The vaccine showed virtually no effectiveness overall, making it extremely unlikely that it could be approved for use without further trials. (sun-sentinel.com)
  • By including, however, the seven people who turned out to have had HIV at the start of the trial (two in the placebo group and five in the vaccine group), the effectiveness drops to 26.4 percent. (scientificamerican.com)
  • One option is to continue with basic research using animal models, before testing the effectiveness of a vaccine on people, said Koff. (newscientist.com)
  • VaxGen may have overstated the effectiveness of its AIDS vaccine because it did not make the proper statistical adjustments to its data, an expert consulted by the company said Wednesday. (sfgate.com)
  • These tests will focus on immune responses and effectiveness of the vaccine in two more phases. (bio.org)
  • The Picker lab is now investigating the possible reasons why only a subset of the animals treated had a positive response in hopes that the effectiveness of the vaccine candidate can be further boosted. (innovations-report.com)
  • A research group in Atlanta has developed an AIDS vaccine that shows 96 percent effectiveness in non-human, pre-clinical trials. (howstuffworks.com)
  • The vaccine "induced robust (high levels of) immune responses in humans," said Barouch. (yahoo.com)
  • and * to promptly evaluate promising candidate vaccines in animal models and, if warranted, in humans. (nih.gov)
  • The NIAID AIDS Vaccine Clinical Trials Network conducts trials in humans to determine the safety of and immune responses stimulated by experimental HIV vaccines (Phase I and Phase II trials). (nih.gov)
  • This is the first demonstration of protection in humans and one of the most significant findings in HIV vaccine research in many years,' Esparza said. (sun-sentinel.com)
  • Dr. MARGARET JOHNSTON (Director, U.S. National Institutes of Health): While we had promising test tube results, when we actually went into humans, the vaccine did not perform as we had hoped. (npr.org)
  • GM-CSF is a cytokine (growth stimulating protein) that serves to expand and mature cells that initiate immune responses and has undergone extensive testing in humans for cancer vaccines. (medicalnewstoday.com)
  • There has never been a vaccine against a retrovirus in humans, so this is a new paradigm. (cnn.com)
  • However, vaccines that protect monkeys against a related disease have been successful, so we believe that there must be a route to a vaccine for humans. (baltimoresun.com)
  • The hope is that the results in the nonhuman primate models will translate into vaccine-induced prevention in humans. (scienceblog.com)
  • A vaccine trial in Thailand (RV144) completed in 2009 showed a modest degree of protection against HIV in humans. (rxpgnews.com)
  • In these patients, a prime-boost vaccine strategy may induce both humoral and cell-mediated immunity. (clinicaltrials.gov)
  • The vaccine did induce some new immune responses," Dr. Schwartz said. (baltimoresun.com)
  • This study will involve 48 healthy volunteers who will receive either two or three immunizations and who will be followed to assess the safety and immunogenicity of the vaccine," explains Lindsey R. Baden, MD, Assistant Professor of Medicine at BWH and Harvard Medical School and Protocol Chair for the study. (biologynews.net)
  • The vaccine is designed to promote a memory immune response against the three major proteins (Gag, Pol, Env) expressed by HIV. (emory.edu)
  • Dr. Robert Schooley, infectious-disease chief at the University of Colorado, said the vaccine's safety and immune response are "what many of us hoped we'd be seeing when this trial started," though he cautioned that it is still "a long way from here to giving a vaccine that could protect people. (foxnews.com)
  • WILSON: In the laboratory and test tubes, it looked as if the blood cells injected with this vaccine would attack HIV-infected cells, suggesting that the vaccine did stimulate an immune response. (npr.org)
  • Many vaccines are made with killed or weakened viruses, but 'killed HIV' doesn't work well to produce an immune response in the body. (clickondetroit.com)
  • A scientific team from the Johns Hopkins School of Medicine reported a year ago that the vaccine had stimulated an immune response in many of its uninfected volunteers. (baltimoresun.com)
  • Simplify your Rite Aid online account login. (riteaid.com)
  • When you select Remember Me, Rite Aid will install a cookie on your computer. (riteaid.com)
  • You are leaving the main Rite Aid website to visit our photo site. (riteaid.com)
  • Rite Aid pharmacists are unique because they understand the importance of personalized care. (riteaid.com)
  • See below for a complete list of vaccine preventable diseases that Rite Aid can immunize against. (riteaid.com)
  • Rite Aid announced on Friday that it will begin administering vaccines at all 2,500 of its stores in 17 states across the U.S. The vaccines will be open to all eligible U.S. citizens aged 16 years or older. (consumeraffairs.com)
  • The availability of vaccines in every Rite Aid location is a major milestone in our ongoing effort to fight COVID-19. (consumeraffairs.com)
  • A likely set of candidates has come to light in a new study in San Francisco for the AIDS Behavioral Research Project. (latimes.com)
  • Those aren't vaccine candidates yet, buy they're really helping to develop new approaches. (voanews.com)
  • There are currently 12 vaccine candidates in human trials. (aljazeera.com)
  • and (3) the evaluation of vaccine candidates in early phase clinical trials. (nih.gov)
  • However, of the 30 vaccine candidates being researched in 19 countries, only one has reached the final testing phase. (thebody.com)
  • In tests in 24 rhesus monkeys at Yerkes, the vaccine successfully contained a highly virulent hybrid of simian and human immunodeficiency viruses (SHIV). (emory.edu)
  • Well, the basic premise of the book is that those diseases that are caused by viruses which are cancer, leukaemia, lymphoma, aids being a form of leukaemia and not anything all that exciting. (whale.to)
  • When we vaccinate a person or sue biologic products we not only inject the vaccine or the anti-biotic or the insulin but we inject a host of viruses that come with it. (whale.to)
  • Most vaccines protect against viruses that enter the body through the respiratory or gastrointestinal systems, but HIV enters the body through genital surfaces or blood. (clickondetroit.com)
  • Extensive testing has been conducted with live vaccines to determine if immunization would be effective at prevention, but they are not suitable for human use due to the potential that the vaccine viruses could mutate and reacquire the ability to cause disease. (bio-medicine.org)
  • The search for an AIDS vaccine is showing renewed promise with a report that a vaccine test on monkeys has been effective. (redorbit.com)
  • Primate research laboratories answer HIV vaccine-related questions by testing HIV and HIV-like vaccines in chimpanzees and monkeys. (nih.gov)
  • His bottom line: At this stage, the vaccine appears to trigger the same immune system response in people that it does in newly immunized monkeys, though the volunteers have not been put to the crucial challenge of exposure to HIV. (foxnews.com)
  • The vaccine was tested in hundreds of mice, guinea pigs and rabbits, as well as 12 Rhesus monkeys and 2 chimpanzees. (nytimes.com)
  • But instead of ending the experiment at this point - assuming that the vaccine conferred protection for only 100 days - Letvin and his VRC colleagues decided to follow the monkeys for an additional 750 days, a total of 850 days or nearly three years. (emaxhealth.com)
  • The vaccine, he asserts, was made with tissues from Asian rhesus monkeys, whose kidney cells do not support SIV. (dynamicchiropractic.com)
  • It is being tested through the use of a non-human primate form of HIV, called simian immunodeficiency virus, or SIV, which causes AIDS in monkeys. (innovations-report.com)
  • About 50 percent of monkeys given highly pathogenic SIV after being vaccinated with this vaccine became infected with SIV but over time eliminated all trace of SIV from the body. (innovations-report.com)
  • May 20-Multiple Norman community groups will host a Mutual Aid Fair Saturday in the parking lot of Irving Middle School, where residents can receive free groceries, hygiene products and the COVID-19 vaccine. (yahoo.com)
  • UNITED NATIONS, June 14 (Reuters) - Outgoing U.N. aid chief Mark Lowcock slammed the Group of Seven wealthy nations on Monday for failing to come up with a plan to vaccinate the world against COVID-19, describing the G7 pledge to provide 1 billion doses over the next year as a "small step. (reuters.com)
  • Since there is currently no vaccine available for COVID-19. (riteaid.com)
  • Photo (c) hapabapa - Getty Images Consumers now have another place to go if they're looking for a COVID-19 vaccine. (consumeraffairs.com)
  • The availability of these walk-in appointments provides another way for those with limited or no technology access to more easily obtain COVID vaccines. (consumeraffairs.com)
  • One can hope that having a new outlet for COVID-19 vaccines might help entice some consumers who have delayed getting their next dose. (consumeraffairs.com)
  • Is HIV/AIDS similar in any ways to COVID-19? (clickondetroit.com)
  • The similarities are minimal, but there are a couple of ways HIV/AIDS and COVID-19 are alike, according to Forbes . (clickondetroit.com)
  • The US funding will enable it to produce at least 1 billion doses of COVID-19 vaccines by the end of 2022, the White House said. (moneycontrol.com)
  • You guys, all this bad news about #Covid_19 but you're burying the lede here…apparently there's an AIDS vaccine! (hollywoodlife.com)
  • Start with a free immunization evaluation to see what vaccines you need. (riteaid.com)
  • ABUJA, Nigeria (Reuters) --Three states in northern Nigeria have suspended a polio immunization program led by the World Health Organisation (WHO) because they feared it spread AIDS and caused infertility, Nigerian officials said on Monday. (scribd.com)
  • Three groups of patients receive dose-escalation (0.5mg, 2mg or 4mg) intramuscular injections of DNA vaccine (D-GPEi) respectively, the other three groups of patients receive dose-escalation (3×10^7pfu, 1×10^8pfu or 3×10^8pfu) intradermal injections of MVA vaccine (M-GPE), two weeks post immunization of lower dose, if the vaccine is safe and well tolerant, the next dose of immunization will begin. (clinicaltrials.gov)
  • The pharmaceutical giant has made the vaccine available at discounted prices under the Global Alliance for Vaccines and Immunisation (GAVI) - an international public-private partnership to improve access to vaccines in the world's poorest countries. (reuters.com)
  • One big winner today seems to be GAVI - the Global Alliance for vaccines and immunisations - which Save the Children is supporting strongly. (savethechildren.org.uk)
  • It's not about finding a way to make profits," says Ms. Johnston, because there will be pressure to offer successful vaccines at or below cost to the world's poor. (crainsnewyork.com)
  • More than 30 million individuals - a majority in the world's developing nations - have died of AIDS since it was first identified 25 years ago. (emaxhealth.com)
  • AIDS remains one of the world's most devastating health problems, with an estimated 33.2 million people living with HIV/AIDS and 2.5 million new infections reported in 2007 alone. (biologynews.net)
  • Q: Is the lack of an AIDS vaccine largely the consequence of the world's biggest pharmaceutical companies standing on the sidelines because there are no huge profits to be made selling vaccines to the less-developed world? (baltimoresun.com)
  • The ride raises awareness and vital funds for HIV/AIDS vaccine research having donated to date over $2.4 million to the Emory Vaccine Center, one of the world's leading vaccine research centers working to find an HIV vaccine. (wikipedia.org)
  • The AIDSVax vaccine, developed by VaxGen, has already been given to 7,900 volunteers in America, Europe and Thailand. (foxnews.com)
  • VaxGen, a small biotechnology company, was formed to carry the vaccine forward after the National Institutes of Health and the company that invented the vaccine, Genentech, decided it was not worthy of clinical trials. (sun-sentinel.com)
  • In 2003 results finally came in from a phase III clinical trial of a gp120 vaccine manufactured by VaxGen: It failed to prevent infections or reduce the number of virus particles circulating in the blood. (scientificamerican.com)
  • VaxGen reported Monday that its vaccine was ineffective overall in a trial of 5,400 participants. (sfgate.com)
  • In nonhuman primates, the GM-CSF-enhanced vaccine achieved protection against SIV in 70% of the animals. (medicalnewstoday.com)
  • Robinson now leads the effort at GeoVax on manufacture and human testing of the vaccine while Amara leads the nonhuman primate component at Emory. (scienceblog.com)
  • The five-year program project grant of more than $26 million from the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, will fund the Emory Consortium for AIDS Vaccine Research in Nonhuman Primates. (rxpgnews.com)
  • There's no instant gratification with vaccines," says Weill Cornell Medical College's immunology professor John Moore, who is searching for an antimicrobial agent that kills the virus on contact. (crainsnewyork.com)
  • Big programs, one called the Center for HIV Vaccine Immunology?and another, the Gates Foundation, funded a collaboration for AIDS vaccine discovery. (voanews.com)
  • Harriet L. Robinson, PhD, chief scientific officer at GeoVax Labs, Inc., and former director of the division of microbiology and immunology at Yerkes National Primate Research Center, has been leading the research team with Rama Rao Amara, PhD, associate professor of microbiology and immunology, Yerkes National Primate Research Center and the Emory Vaccine Center. (scienceblog.com)
  • We have been here before, with promising candidate vaccines that haven't panned out," he told AFP. (yahoo.com)
  • Federal health experts said the MicroGeneSys vaccine was only the first of several candidate vaccines to reach readiness for first-phase trials. (nytimes.com)
  • Robinson and Amara began their work at Yerkes National Primate Research Center at Emory and the Emory Vaccine Center. (scienceblog.com)
  • The Food and Drug Administration has approved the Emory Vaccine Center's application to begin a Phase I clinical trial of its multiprotein AIDS vaccine. (emory.edu)
  • Pending final approval of the trial by institutional review boards, 30 human volunteers at three sites around the country will begin receiving the vaccine within the next several months. (emory.edu)
  • The trial will compare the effects of high and low dosages of the vaccine in two groups of (HIV negative) volunteers, who will receive two intramuscular injections. (emory.edu)
  • Preliminary results from the Phase I trial of the DNA component of the vaccine should be available by the middle of next year. (emory.edu)
  • A California biotech company, ViCal, manufactured the priming components of the AIDS vaccine for the Phase I clinical trial from the DNA of clade B, the most common HIV subtype in North America and Western Europe. (emory.edu)
  • In late 2003, a Phase I clinical trial of a vaccine against clade AG, the most common HIV subtype found in West Africa, will be launched in the United States and then in Côte d'Ivoire (formerly the Ivory Coast). (emory.edu)
  • The Emory Vaccine Center's Hope Clinic will serve as one of the clinical test sites for this trial. (emory.edu)
  • By late 2004, the Vaccine Center hopes to begin a Phase I trial of a trivalent vaccine incorporating the DNA from clades B, AG, and C. Subtype C is the most prevalent form of HIV in India and southern Africa. (emory.edu)
  • They conceded that the findings, though statistically significant, might change if the vaccine were tested among more members of minorities, who were only a small fraction of the people in the trial. (sun-sentinel.com)
  • Costing $105 million and enrolling more than 16,000 subjects, the Thai clinical trial was the largest AIDS vaccine test to date. (scientificamerican.com)
  • Specifically, 74 people who had received the placebo became infected with HIV in the trial period, compared with the 51 people who became infected after receiving the vaccine, which makes for a protective effect of 31.2 percent. (scientificamerican.com)
  • This contributes more evidence that an AIDS vaccine may be possible," says Jerome Kim of the Walter Reed Army Institute of Research and co-author of the Thai trial study (which appeared in the New England Journal of Medicine in October). (scientificamerican.com)
  • For example, where 3.5 per cent of the population is infected, a trial could include as few as 450 volunteers if the vaccine worked 90 per cent of the time. (newscientist.com)
  • It would be unethical not to warn people receiving trial vaccines against high-risk activities. (newscientist.com)
  • The NIH formed its own HIV vaccine trial network in 2000 to oversee clinical research sites in the U.S., Africa, Asia, the Caribbean and South America. (scientificamerican.com)
  • Dr. JOHNSTON: The other surprising aspect of the trial, and one that's even more perplexing to us, is that more people who received the vaccine got infected than those who received the blank or placebo injection. (npr.org)
  • Deeks and others believe the trial may have been partly successful because the vaccine contains HIV genes that code for "highly conserved" internal structures and enzymes that cannot change much without harming the virus. (sciencemag.org)
  • Detailed results of the now-famous Thai AIDS vaccine trial confirmed that the vaccine is modestly effective, but hinted that its effect may fade over time. (medpagetoday.com)
  • Frahm was not part of the Thai study but presented data at the conference from the other recent large HIV vaccine study, the STEP trial. (medpagetoday.com)
  • Plans for the tests on Tuesday followed large-scale trials in Thailand of another preventative AIDS vaccine failed a late-stage clinical trial. (aljazeera.com)
  • It has been proposed to initiate a HIV/AIDS trial in Kericho, as a collaborative work between Kenya Medical Research Institute (KEMRI) and Walter Reed Foundation within the next two months. (medindia.net)
  • Late last week, the NIH's linkurl:AIDS Vaccine Research Subcommittee;http://www3.niaid.nih.gov/research/topics/HIV/vaccines/advisory/avrs/ voted 23-3 in favor of beginning the PAVE 100 HIV vaccine trial. (the-scientist.com)
  • HIV/AIDS agency, describe the trial results as 'compelling. (psmag.com)
  • A phase 1 clinical trial to test a novel HIV/AIDS vaccine has begun at Brigham and Women's Hospital (BWH). (biologynews.net)
  • Trial results that were released in September 2009 found the vaccine was 31% effective in preventing HIV infections. (cnn.com)
  • The vaccine trial took an unconventional approach to HIV. (baltimoresun.com)
  • One other AIDS vaccine trial in the United States takes this approach. (baltimoresun.com)
  • In 16 days, all 801 volunteers had been told whether they got the vaccine or not. (npr.org)
  • To date, over 40 different HIV vaccines have been tested in several thousand volunteers. (aidsmap.com)
  • Then the volunteers were given booster injections -- at weeks 12 and 24 -- of a second vaccine, dubbed AIDSVAX B/E, or placebo. (medpagetoday.com)
  • But seven volunteers -- five in the vaccine arm and two in the placebo arm -- were found to have been HIV-positive at the start of the study and were excluded from the main analysis, of the "modified" intent-to-treat population. (medpagetoday.com)
  • Small-scale human tests of other AIDS vaccines have already started in Zaire and France, but the new study, to be conducted with 81 volunteers who will be treated at the Clinical Center of the National Institutes of Health, in Bethesda, Md., is the first authorized in the United States. (nytimes.com)
  • Of more than 50 therapeutic vaccine trials so far, this is the first one that has bolstered the immune system in a "meaningful" way, says Steven Deeks, an HIV/AIDS clinician and researcher at the University of California, San Francisco, who is "cautiously optimistic" that the data will inspire others to study the approach. (sciencemag.org)
  • A French scientist awarded the Nobel Prize for discovering the Aids virus has predicted there would be a 'therapeutic vaccine' for the disease within four years. (dailymail.co.uk)
  • I think it will be possible with a therapeutic vaccine rather than preventative vaccinations. (dailymail.co.uk)
  • A therapeutic vaccine prevents disease from flourishing after it has taken hold. (dailymail.co.uk)
  • Joel Blankson, who led the study, said that the role of the woman's immune system is a "good sign in terms of developing a therapeutic vaccine," which would not prevent transmission of the virus but could be used to prevent HIV-positive people from progressing to AIDS (Fox, Reuters , 8/12). (emaxhealth.com)
  • Of 90 of the first reported cases of HIV and AIDS acquired in specific towns in Africa through 1981, 76 came from the same towns where the experimental vaccine was given or within 100 miles of them. (dynamicchiropractic.com)
  • The experimental vaccine was manufactured by MicroGeneSys Inc. of Meriden, Conn. (baltimoresun.com)
  • From testing drugs to developing vaccines, the close study of the immune system is key to improving real-world health outcomes. (lifeboat.com)
  • Plans for the first human trials in this country of an experimental AIDS vaccine were announced today by Federal officials and a Connecticut company that developed the substance. (nytimes.com)
  • The GeoVax vaccine, developed on the campus of Emory University, is already in Phase I human trials and could be on the market by 2011. (howstuffworks.com)
  • A vaccine has proven elusive as the human immunodeficiency virus (HIV) mutates easily and can hide away in cells, evading the immune system, only to reemerge and spread years later. (yahoo.com)
  • The news agency said, the compound vaccine consists of DNA vaccine and regrouped virus carrier. (chinadaily.com.cn)
  • They found that human body will become immune to AIDS virus after injecting DNA vaccine and regrouped virus carrier in succession. (chinadaily.com.cn)
  • Currently, even the "cocktail treatment", the most effective measure to deal with AIDS so far, can only stabilize or ease the AIDS symptoms instead of killing the virus in the body. (chinadaily.com.cn)
  • SEATTLE - The first preliminary human testing of a highly anticipated new kind of AIDS vaccine offers tantalizing hints it may ultimately protect against the killer virus. (foxnews.com)
  • It is a more traditional vaccine, made from the outer wrapper of the AIDS virus. (foxnews.com)
  • The vaccine, known as Aidsvax, is made from a protein called gp120, the same protein that protrudes from the surface of HIV and helps the virus dock with cells of the body's immune system. (sun-sentinel.com)
  • Since the vaccine consists of only one protein and not the whole virus, it cannot give someone AIDS. (sun-sentinel.com)
  • A chameleon killer, the virus mutates so rapidly that it has vanquished any effort to create an effective vaccine against it for two decades now. (thestar.com)
  • At that time, the Human Immunodeficiency Virus (HIV) virus that causes AIDS had infected some 25 million people worldwide. (scientificamerican.com)
  • But they hope it will weaken the virus enough to delay the complications of AIDS and reduce the need for expensive antiretroviral drugs. (scientificamerican.com)
  • The vaccine is made by combining elements of the cold virus with fragments of HIV. (npr.org)
  • Both trials will test very similar vaccine regimes: a dose of canary pox virus engineered to express HIV-1 proteins, followed by a booster shot of the HIV protein gp120. (rense.com)
  • The two-decade search for an AIDS vaccine is in crisis after two field tests of the most promising contender not only did not protect people from the virus but may actually have put them at increased risk of becoming infected, The Washington Post reported. (freerepublic.com)
  • There will never be a cure for this virus only treatment of symptoms, they are throwing money down a rat hole looking for a vaccine. (freerepublic.com)
  • The effect of the HB vaccine inactivation process on the AIDS virus and two other human retroviruses (HTLV-I and HTLV-II) was studied. (cdc.gov)
  • Heat, an inactivation step used in vaccines manufactured outside the United States, has also been shown to inactivate the AIDS virus (4). (cdc.gov)
  • The second approach, which attempted to detect AIDS virus-related nucleic acid sequences using dot blot hybridization analysis of the vaccine with an AIDS virus deoxyribonucleic acid (DNA) probe, was done at MSD using as a positive control infected cellular (ribonucleic acid) RNA preparations provided by CDC. (cdc.gov)
  • The vaccine contained no detectable AIDS virus-related sequences at a sensitivity of less than one picogram of DNA per 20-ug dose of vaccine. (cdc.gov)
  • Paired sera were examined at CDC using a highly sensitive and specific ELISA assay for the AIDS virus. (cdc.gov)
  • Creating live attenuated vaccines normally involves deleting genes that protect the virus against the immune system, but which are not essential for its reproduction. (aidsmap.com)
  • It's the proof of concept that through therapeutic vaccination we can really re-educate our T cells to control the virus," says Beatriz Mothe, a clinician at IrsiCaixa AIDS Research Institute in Barcelona, Spain, who presented the results here at the Conference on Retroviruses and Opportunistic Infections. (sciencemag.org)
  • This, in turn, should make it easier for them to contain the virus if ARVs are stopped-especially with a helping hand from a vaccine. (sciencemag.org)
  • A vaccine that treats a virus? (newser.com)
  • If virology ever gets to the point they can create a safe and reliable vaccine to treat virus' the world would be better served by a common cold vaccination. (newser.com)
  • The latest vaccine is based on tat, a small protein essential for the virus replication and aims to stop the disease spreading. (aljazeera.com)
  • Feline immunodeficiency virus, also known as cat AIDS , is a disease of the immune system present in roughly 10 percent of cats. (vetinfo.com)
  • Almost 30 years after its discovery, the incurable AIDS virus continues to destroy lives around the globe. (columbiachronicle.com)
  • He said he was concerned the vaccine 'can give the AIDS virus and that it contains contaminants that are likely to cause cancer in the human body. (scribd.com)
  • Voters in San Francisco - the city that has probably suffered from AIDS more grievously than any other in America - may soon vote on whether to ban a safe, one-time procedure that protects against the virus that causes AIDS almost as effectively as the annual flu shot protects against the flu. (psmag.com)
  • Abstract Acquired Immunodeficiency Syndrome (AIDS), caused by Human Immunodeficiency virus (HIV), is a life-threatening disorder that persists worldwide as a severe health problem. (medworm.com)
  • For years, the HIV vaccine field has been working with vaccines that elicited immune responses that primarily controlled immunodeficiency virus challenges in infected animals, but did not actually prevent infections," said Dr. Harriet Robinson, Chief Scientific Officer at GeoVax. (medicalnewstoday.com)
  • A vaccine usually targets a virus in a particular form, but won't work when the virus changes. (clickondetroit.com)
  • Ever since it was first recognized by American doctors in 1981, the origin of the virus that causes AIDS -- a disease that has killed as many as 16 million people and infected another 36 million worldwide -- has been one of the great mysteries of science. (dynamicchiropractic.com)
  • The bodies of some people make these immune system proteins after they are infected with the AIDS virus, when it is too late for them to do much good. (lifescript.com)
  • What we are trying to do with a vaccine is get ahead of the virus. (lifescript.com)
  • It has been almost impossible to make a vaccine that will affect the virus. (lifescript.com)
  • 2005. A noninfectious simian/human immunodeficiency virus DNA vaccine that protects macaques against AIDS. (bio-medicine.org)
  • We still don't know if boosting your immunity will have the effect of slowing down the destructive effect of HIV [the human immunodeficiency virus]," Dr. Gale Smith, vice president of the company that produced the vaccine, said yesterday. (baltimoresun.com)
  • At best, he said, the vaccine would prolong lives by slowing the pace at which the virus destroys the immune system. (baltimoresun.com)
  • Typically, a vaccine is designed to protect people from contracting a virus, such as the one that causes polio or measles. (baltimoresun.com)
  • The MicroGeneSys vaccine, made from a piece of the virus' outer coating, is being tried on virus-free patients at several other research centers. (baltimoresun.com)
  • The AIDS virus depletes a person's storehouse of these cells, making the patient prone to a variety of illnesses that ultimately become fatal. (baltimoresun.com)
  • There has never, to this date, been a proper isolation and purification of the human immunodeficiency virus, and one might be justified in saying that there is no AIDS epidemic, but rather an iatrogenic (doctor caused) epidemic of drug-induced deaths and a lot of unnecessary fear and suffering, all based on very wonky science. (newmediaexplorer.org)
  • If every part of the HIV is mutable and is mutating, it will never become an infective virus or the virulent virus it was made out to be when they first claimed that they had a virus, which "was the probable cause of AIDS. (newmediaexplorer.org)
  • It was a crime against humanity that the virus was unleashed on the world, and it continues to be a crime that the vaccine has been kept secret and for private use only. (mondovista.com)
  • The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine. (moneycontrol.com)
  • An Atlanta research collaboration may be one step closer to finding a vaccine that will provide long-lasting protection against repeated exposures to human immunodeficiency virus (HIV). (scienceblog.com)
  • The vaccine is designed for a version of the virus prevalent in the Americas. (scienceblog.com)
  • There is no cure for AIDS, or a vaccine, but strict adherence to anti-retroviral therapy by individuals with HIV-1 (the virus that causes AIDS) can prolong life, slow the disease's progress, and prevent complications. (hollywoodlife.com)
  • T-cells are a key component of the body's immune system, which fights off disease, but T-cells elicited by conventional vaccines of SIV itself are not able to eliminate the virus. (innovations-report.com)
  • The virus is going escape the immune-system response triggered by the vaccine. (howstuffworks.com)
  • In order to stop the virus from escaping, the GeoVax vaccine uses a two-step method to trigger and then boost the two primary immune responses in the human body. (howstuffworks.com)
  • Emory University has an equity interest in GeoVax and is entitled to sales royalties for the vaccine technologies being studied. (scienceblog.com)
  • Hunter is a member of the Emory Vaccine Center, a co-director of the Emory Center for AIDS Research, a professor of pathology and laboratory medicine at Emory University School of Medicine, and a Georgia Research Alliance Eminent Scholar. (rxpgnews.com)
  • The ride originally traveled from the Hope Clinic in Decatur, GA to Athens, GA. To accommodate more riders, in 2007, ride organizers changed the route to begin and end on the Emory University campus with a Saturday night stay at Rock Eagle near Eatonton, GA. In 2009, the name of the ride was changed to the AIDS Vaccine 200 to communicate more clearly the purpose of the ride. (wikipedia.org)
  • After several, much-publicized vaccine failures, Koff says 'the field has basically struggled in vaccine design,' using antibody immunity. (thestar.com)
  • It takes about 2 weeks for the body to develop immunity after vaccine administration, so it's best to get a flu shot sometime in the fall, but by the end of October if possible. (riteaid.com)
  • Jamie Scott , a Simon Fraser University professor and Canada Research Chair in molecular immunity, and three international collaborators are getting a hefty financial boost in their efforts to develop an effective HIV/AIDS vaccine. (sfu.ca)
  • This new vaccine aims to overcome the problem of preexisting immunity to common vaccine vectors, which is thought to be a major problem in the developing world. (biologynews.net)
  • To help reach this goal, the National Institute of Allergy and Infectious Diseases (NIAID), which spearheads federal funding for biomedical research on HIV/AIDS for the National Institutes of Health (NIH), has intensified its HIV vaccine research program. (nih.gov)
  • Although traditional investigator-initiated research forms the foundation for HIV/AIDS vaccine research, NIAID supports several special initiatives to accomplish specific research objectives. (nih.gov)
  • The study would be conducted by the linkurl:Partnership for AIDS Vaccine Evaluation;http://www.hivpave.org/ (PAVE), which is a consortium of government agencies and government-funded organizations involved in HIV vaccine research, and is sponsored by NIAID. (the-scientist.com)
  • These studies on single-dose vaccines for emerging infectious diseases were supported with funding from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) and performed at laboratories of the Centers for Disease Control, (CDC) in Fort Collins, CO, Institute of Human Virology, University of MD and NIH's Rocky Mountain Laboratories have demonstrated the broad utility of the platform. (eurekalert.org)
  • The HIV Vaccine Trials Network of the National Institute of Allergy and Infectious Diseases will fund the initial Phase I trials. (emory.edu)
  • HIV Vaccine Trials Network and the Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. (lww.com)
  • Production of the vaccine against subtype AG will be overseen by GeoVax Inc., the startup company founded by Emory and the Vaccine Center for manufacture of the vaccine. (emory.edu)
  • Based in Atlanta, GeoVax Labs, Inc. is a biotechnology company developing human vaccines for diseases caused by HIV and other infectious agents. (medicalnewstoday.com)
  • The regimen builds on the GeoVax DNA/MVA vaccine that is currently in Phase 2a clinical testing through the HVTN. (medicalnewstoday.com)
  • Unlike other vaccine technologies currently available, which sacrifice confidence in success for speed or vice-versa, the GeoVax technology offers a true "Plug and Play" platform approach that is well suited for use against a wide range of biological threats and amenable to rapid, large-scale production," said Rahul Basu, scientist at GeoVax and lead author on the study. (eurekalert.org)
  • A first generation GeoVax DNA/MVA vaccine that does not co-express GM-CSF has shown excellent safety and reproducible vaccine responses in Phase 1 and 2a clinical trials in more than 400 uninfected people. (scienceblog.com)
  • Emory and GeoVax, and Drs. Robinson and Amara, may financially benefit if GeoVax is successful in developing and marketing its vaccines. (scienceblog.com)
  • Montagnier, 76, said a treatment could be possible in the future with a 'therapeutic' rather than preventive vaccine for which results might be published in three or four years if financial backing is forthcoming. (dailymail.co.uk)
  • These included prophylactic and therapeutic vaccines for HIV (already in advanced clinical trials), preventive vaccines for Marburg, Sudan and Malaria, all with major epidemic potential with high human lethality, as well as therapeutic vaccines for chronic hepatitis B infections and tumor-associated antigen (TAA)-based-cancer vaccines. (eurekalert.org)
  • Developing a safe and effective preventive HIV/AIDS vaccine is still a critical part of the fight against this challenging disease that affects more than 30 million people worldwide, says Eric Hunter, PhD, who will lead the consortium. (rxpgnews.com)
  • Ten years ago today, President Bill Clinton announced a national goal to develop an AIDS vaccine within a decade. (scientificamerican.com)
  • But with the strides of recent years, it is no longer a question of whether we can develop an AIDS vaccine, it is simply a question of when . (scientificamerican.com)
  • Even a modestly effective vaccine like that would have a huge impact here. (ibtimes.com)
  • In it, John Moore, an AIDS researcher at Cornell University's Weill Medical College in New York City, argues that one of the two vaccine trials planned for 2002 should be scrapped. (rense.com)
  • Action Cycling Atlanta, Inc. (ACA) was formed in 2003 by a group of cyclists who had participated in the 2002 European AIDS Vaccine Ride, one of the last AIDSRides produced by Pallotta Teamworks. (wikipedia.org)
  • According to experts, AIDS vaccine is the only solution to stop the wildfire spread of the grievous infectious disease. (chinadaily.com.cn)
  • New York city is really important in the search for a vaccine," says Beryl Koblin, head of the Laboratory of Infectious Disease Prevention for the New York Blood Center. (crainsnewyork.com)
  • Led by the National Institute of Allergy and Infectious Diseases external icon , HIV Vaccine Awareness Day (HVAD) is observed on May 18. (cdc.gov)
  • Dr. Anthony S. Fauci, director of the National Institute for Allergy and Infectious Diseases, said there was ''really no change in the timetable'' previously issued by health experts that a useful vaccine would probably ''not be widely available'' until ''well into the 1990's. (nytimes.com)
  • Vaccines are the most effective means of preventing and even eradicatiing infectious diseases. (ndtv.com)
  • This program is sponsored by the Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health. (biologynews.net)
  • To demonstrate a broad utility of the platform, we developed prophylactic and therapeutic vaccines for other infectious diseases as well as cancer," said Mr. Basu. (eurekalert.org)
  • I am more optimistic about an AIDS vaccine at this point in time than I have been probably in the last 10 years," Dr. Gary Nabel of the National Institute of Allergy and Infectious Diseases, who led the study, said in a telephone interview. (lifescript.com)
  • A: The U.S. government has put more money into AIDS research than it has put into work on any other infectious agent. (baltimoresun.com)
  • Dr. Michael Lange, associate chief of infectious diseases at St. Luke's-Roosevelt Hospital in New York and one of the doctors the FDA consulted when evaluating AZT in 1987, says even he sometimes had trouble differentiating between AZT's toxic effects and AIDS itself. (newmediaexplorer.org)
  • But one government AIDS researcher, who didn't want to be identified, was angered by Moore's charges. (rense.com)
  • Col. Nelson Michael, another vaccine researcher, explained that different types of antibody responses in the body determine who gets infected and who does not. (columbiachronicle.com)
  • Dr. David Schwartz, a Hopkins vaccine researcher, said it was important to keep the Walter Reed results in perspective. (baltimoresun.com)
  • The measles vaccine is an example. (aidsmap.com)
  • Vaccine-associated measles pneumonitis in an adult with AIDS. (nih.gov)
  • With the highest number of AIDS cases in the nation, New York City has long held center stage in infections. (crainsnewyork.com)
  • In the modified intent-to-treat population, there were 51 infections in the vaccine arm and 74 in the placebo arm, a 31.2% reduction that was significant at P =0.04. (medpagetoday.com)
  • Finally, in the smaller per-protocol population, there were 36 infections in the vaccine arm and 50 in the placebo arm. (medpagetoday.com)
  • Thanks to anti-retroviral therapy and its ability to control the spread of HIV and AIDS, the number of new HIV infections fell 37% and HIV-related deaths 45% between 2000 and 2018, according to the World Health Organization . (clickondetroit.com)
  • According to the World Health Organization (WHO), in 2009 33.3 million people were living with HIV, there were 2.6 million new infections and 1.8 million AIDS-related deaths worldwide. (cnn.com)
  • Human body test, or stage I clinical test, of the compound AIDS vaccine aims to further assess the security of the vaccine, an SFDA official said. (chinadaily.com.cn)
  • As Dr. Lawrence K. Altman wondered earlier this year, who will test such a vaccine? (latimes.com)
  • Dr. Leon McKusick, a psychologist with the University of California at San Francisco, has surveyed 644 homosexual men about their willingness to participate in a test of an AIDS vaccine. (latimes.com)
  • Many of those surveyed by McKusick have not taken the antibody test--a blood test that indicates if the subject has been exposed to AIDS. (latimes.com)
  • But he considers his gig at NYU Medical Center at least as important: volunteering to test a possible AIDS vaccine. (crainsnewyork.com)
  • Trials to test whether potential AIDS vaccines can prevent the disease should begin as soon as possible, without waiting to find out precisely how they work. (newscientist.com)
  • A spokesman for the F.D.A. said two other vaccine developers, Oncogen, a Seattle-based subsidiary of Bristol-Myers, and a team that includes the Institute for Immunologic Disorders in Houston, had also sought approval to test AIDS vaccines. (nytimes.com)
  • The objective of a Phase II test is to assess whether a drug has any impact whatsoever on the intended disease (i.e., does it do anything vis-à-vis AIDS). (ahrp.org)
  • The National Biodefense Safety Board (NBSB) recently voted to move forward with an administration plan to test an anthrax vaccine on American children . (westernjournalism.com)
  • And because the test kits were bogus kits, they carry a disclaimer that states - "these test kits cannot be used to diagnose AIDS" which was good advice from their lawyers to protect their ass from lawsuits. (newmediaexplorer.org)
  • MacDonald, who has been front and centre in the global search for AIDS vaccines, did not contribute to the paper. (thestar.com)
  • The long search for an AIDS vaccine has produced countless false starts and repeated failed trials, casting once bright hopes into shadows of disenchantment. (scientificamerican.com)
  • 2001-03-04T08:31:33-05:00 https://images.c-span.org/defaults/capitol.jpg Mr. Cohen discussed his book Shots in the Dark: The Wayward Search for an AIDS Vaccine , published by W.W. Norton. (c-span.org)
  • Mr. Cohen discussed his book Shots in the Dark: The Wayward Search for an AIDS Vaccine , published by W.W. Norton. (c-span.org)
  • In a Washington Post letter to the editor , Alan Bernstein, executive director of the Global HIV Vaccine Enterprise, and Rafi Ahmed, science committee chairman of the Global HIV Vaccine Enterprise, challenge a recent Washington Post editorial that questioned the scientific progress being made in the search for an HIV vaccine and microbicide. (kff.org)
  • Since the initial proof-of-concept studies examining the ability of antigen-encoded plasmid DNA to serve as an immunogen, DNA vaccines have evolved as a clinically safe and effective platform for priming HIV-specific cellular and humoral responses in heterologous "prime-boost" vaccination regimens. (mdpi.com)
  • Two government agencies in the US are about to waste tens of millions of dollars by running separate trials of almost identical AIDS vaccination regimes, claims a controversial commentary in the journal Nature. (rense.com)
  • Childhood vaccination has saved many lives, yet lots more has to be done to increase awareness and eliminate myths regarding vaccines. (medindia.net)
  • Pfizer's vaccine protects children and adults from 13 types of pneumococcal bacteria, and a full vaccination course costs about $170 on India's private market. (reuters.com)
  • The vaccines are suitable for repeated use, stable at refrigerator temperatures or lyophilized for non-cold chain needle-free application, and amenable to rapid and affordable scale-up for use in both epidemic response and routine vaccination. (eurekalert.org)
  • Vaccination consisted of two DNA inoculations at months 0 and 2 to prime the vaccine response and then two booster inoculations at months 4 and 6. (scienceblog.com)
  • There is a great deal of interest in enhancing the immunogenicity of DNA by engineering DNA vaccines to co-express immune modulatory adjuvants. (mdpi.com)
  • There has been such widespread homophobia in the wake of the AIDS epidemic that it is important for the general population to appreciate that among a substantial number of homosexuals there is a strong sense of compassion and responsibility. (latimes.com)
  • AIDS epidemic is greater than the need to do basic research on HIV. (newscientist.com)
  • Such a vaccine, along with existing HIV treatment and prevention strategies, would help achieve the goal of ending the HIV epidemic. (cdc.gov)
  • Ending Aids takes a hard look at one of medicine's most challenging struggles: the HIV/AIDS epidemic. (macfound.org)
  • However, AIDS still remains an epidemic burden to developing nations where a startling 33 million people were said to be living with HIV. (medindia.net)
  • In 1995, the AIDS epidemic peaked in the U.S., with a reported 50,000 deaths that year, according to the Centers for Disease Control and Prevention . (clickondetroit.com)
  • We need a vaccine if we are going to end the epidemic. (cnn.com)
  • Q: Because a vaccine is a long way off at best, what should countries do to minimize the impact of this epidemic? (baltimoresun.com)
  • In the early days the AIDS posse said that entire nations, especially in North Africa, will disappear due to the AIDS epidemic. (newmediaexplorer.org)